Pyruvate kinase activators for use in therapy.
5 claims: 3 independent, 2 dependent
- 1Un compuesto para usarse en el tratamiento de anemia hemolitica en un paciente que lo necesite, en donde una cantidad efectiva del (1) compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo o (2) una composición farmacéuticamente aceptable que comprende un compuesto de fórmula I o una sal del mismo, y un portador farmacéuticamente aceptable, se pone en contacto con la sangre de dicho paciente extracorpóreamente, en donde:W, X, Y y Z se seleccionan cada uno independientemente de CH o N;D y D 1 se seleccionan independientemente de un enlace o NR b ;A es arilo o heteroarilo, en donde dicho arilo o heteroarilo están no sustituidos o sustituidos con 1 o 2 134 instancias de R 2 ;L es un enlace, -C(O)-, -(CR c R c )m-, -OC(O)-, -(CR c R c )mOC(O)-, - (CR C R C ) m -C (O)-, -NR b C(S)- o -NR b C(O)- (donde el punto de unión a R 1 está en el lado izquierdo);R 1 se selecciona de alquilo, cicloalquilo, arilo, heteroarilo y heterociclilo;cada uno de los cuales está sustituido con 0-5 apariciones de R d ;cada R 2 se selecciona independientemente de halo, haloalquilo, arilo, heteroarilo, alquilo, -OR a , -COOR C , o CONR C R C ;cada R 3 se selecciona independientemente de halo, haloalquilo, alquilo, hidroxilo y OR a , o dos R 3 adyacentes, junto con los átomos de carbono a los que están unidos forman un heterociclilo;cada R a se selecciona independientemente de alquilo, acilo, hidroxialquilo y haloalquilo;cada R b se selecciona independientemente de hidrógeno y alquilo;cada R c se selecciona independientemente de hidrógeno, halo, alquilo, alcoxi y haloalcoxi, o dos R c , junto con los átomos de carbono a los que están unidos forman un cicloalquilo;cada R d se selecciona independientemente de halo, haloalquilo, haloalcoxi, alquilo, alquinilo, nitro, ciano, 135 hidroxilo, -C(O)R a , -OC(O)R a , -C(O)OR a , -SR a , -NR a R b y -OR a , o dos R d , junto con los átomos de carbono a los que están unidos forman un heterociclilo;n es 0, 1 o 2;mes 1, 2 o 3;h es 0, 1 o 2;y g es 0, 1 o 2;
- 2El compuesto para usarse de conformidad con la reivindicación 1, en donde el compuesto o una sal farmacéuticamente aceptable del mismo o la composición farmacéuticamente aceptable se agrega directamente a células de sangre entera o concentrados de eritrocitos extracorpóreamente.
- 3El compuesto para usarse de conformidad con las reivindicaciones 1 o 2, en donde la anemia hemolitica es anemia hemolitica no esferocitica hereditaria.
- 4Un compuesto para usarse en el tratamiento de la anemia falciforme, en donde dicho compuesto comprende (1) un compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo; o (2) una composición farmacéuticamente aceptable que comprende un compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo, y un portador farmacéuticamente aceptable, en donde la fórmula I es como se define en la reivindicación 1. 136 farmacéuticamente aceptable que comprende un compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo, y un portador farmacéuticamente aceptable, en donde la fórmula I es como se define en la reivindicación 1. 6. Un compuesto para usarse en el tratamiento de talasemia; esferocitosis hereditaria; eliptocitosis hereditaria; abetalipoproteinemia; síndrome de BassenKornzweig; hemoglobinuria nocturna paroxismal; anemia hemolítica adquirida; o anemia de enfermedad crónica, en donde dicho compuesto comprende (1) un compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo; o (2) una composición farmacéuticamente aceptable que comprende un compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo, y un portador farmacéuticamente aceptable, en donde la fórmula I es como se define en la reivindicación 1. 7. El compuesto para usarse de conformidad con la reivindicación 6, en donde la talasemia es beta-talasemia. 8. El compuesto para usarse de conformidad con la reivindicación 6, en donde la anemia hemolítica es anemia congénita. 137 9. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho compuesto está representado por la fórmula (I), en donde:W, X, Y y Z se seleccionan cada uno independientemente de CH o N;D y D 1 se seleccionan independientemente de un enlace o NR b ;A es heteroarilo biciclico, en donde el heteroarilo está no sustituido o sustituido con 1 o 2 instancias de R 2 ;L es un enlace, -C(O)-, -(CR c R c )ra-, -OC(O)-, -(CR c R c )mOC(O)-, - (CR C R C ) m -C (O)-, -NR b C(S)- o -NR b C(O)- (en donde el punto de la fijación a R 1 está en el lado izquierdo)-;R 1 se selecciona de alquilo, cicloalquilo, arilo, heteroarilo y heterociclilo;cada uno de los cuales está sustituido con 0-5 apariciones de R d ;cada R 2 se selecciona independientemente de halo, haloalquilo, arilo, heteroarilo, alquilo, -0R a , -COOR C , o CONR C R C ;138 cada R 3 se selecciona independientemente de halo, haloalquilo, alquilo, hidroxilo y OR a , o dos R 3 adyacentes, junto con los átomos de carbono a los que están unidos forman un heterociclilo;cada R a se selecciona independientemente de alquilo, acilo, hidroxialquilo y haloalquilo;cada R b se selecciona independientemente de hidrógeno y alquilo;cada R c se selecciona independientemente de hidrógeno, halo, alquilo, alcoxi y haloalcoxi, o dos R c , junto con los átomos de carbono a los que están unidos forman un cicloalquilo;cada R d se selecciona independientemente de halo, haloalquilo, haloalcoxi, alquilo, alquinilo, nitro, ciano, hidroxilo, -C(O)R a , -OC(O)R a , -C(O)OR a , -SR a , -NR a R b y -OR a , o dos R d , junto con el átomo de carbono al que están unidos forman un heterociclilo;n es 0, 1 o 2;mesl, 2 o 3;h es 0, 1 o 2;y g es 0, 1 o 2;10. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho 139 compuesto está representado por la fórmula (Id): 11. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho compuesto se selecciona de: 140 o o o o o o 141 142 o 144 o 146 147 148 o 149 o o
- 55αχόθνί9 ·χ.ο Λ ο?/? o -íxc a oi/? Αχ Λ °·?·ϊ9 CH3 n 0 ViT) άο Λ Χ) .?- /ο ·=· ó H U \ π 3 υ ΟΗ 10 Ww ο χιχΑΧΧ? 15 ci ο ίχο Λ ο?./ο ch 3 20 -Λχο^ χ9 o QjfVXg) 1 3 C CHa O o v ?o j h 3 c° o n r/O.° I ι,Λ^χ « h 3 c s 150 151 152 ch 3 o 153 154 ch 3 o h 3 c o o 155 10 CH 3 O O 156 o o 157 o o o o o 158 159 160 162 163 164 o o o 166 o 167 o o o o o 168 cu?o^o o o ch 3 h 3 c o o O h 3 c O ,x w 172 173 o 174 175 176 o \ΊΊ 178 179 180 ch 3 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 12. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho compuesto se selecciona de:204 13. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho compuesto es: 14. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho compuesto es: 205 15. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho compuesto es: 16. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho compuesto es: N L .N 17. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho compuesto es: N I H 18. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones l - 8, o una sal 206 farmacéuticamente aceptable del mismo, en donde dicho compuesto es: o 19. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones l - 8, o una sal farmacéuticamente aceptable del mismo, en donde dicho compuesto es: 20. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho compuesto es: 21. El compuesto para usarse de conformidad con cualquiera de las reivindicaciones 1-8, o una sal farmacéuticamente aceptable del mismo, en donde dicho 207 compuesto es:
Independent claims5
1,222 paragraphs in 13 sections, as filed
DIVISIONAL SUB-DIRECTOR OF PATENT FUND EXAMINATION BIOTECHNOLOGICAL, PHARMACEUTICAL AND CHEMICAL AREAS
EMELIA HERNÁNDEZ PRIEGO
<img file="MX367387B_D0001.tif" />
Original string:
EMELIA HERNANDEZ PRIEGO | 00001000000405397295 | Administration Service
Tax | 56 || MX / 2019/70775 | MX / a / 2013/012787 | PCT patent title | 1220 | RRGO | Page (s) 2 | ttLgbQw / Qe5z61 nl8uqJ9CHTE98 =
Digital stamp:
hCkp90IX3quDx4YMIF8FybtngkRFDIUvTefZ0S1 ZeMAkjPk06b92dMWIv7mclaapWr8Wmmnyu6pybiK5aXe0IOGpgn iLc1y9zOkxnqK3Dwo / 5svlFIYLQpkHea8zOZZ2SIHpCpyylk2lwtYTc9mDhwX / AmoXHPdRGwcLmDoNsxD6eNycWgr3
CXco6uUF DEzYpL23oeKaVRhRfl8y82Ean5l + + + fBXHP¡DITTt0nXQb4QBaOOueesyqbB8QWf hrON4ZibPERIO7zUEW a1e3T1 / 7 / PzFJOOOJ6f F4ZF9Dm3kllAh5YAnTFMy + VwscjjNfhgDcrZ1qy¡YaAIRCh6jyg // == * Additional information on the next page.
MX 2019 70775
PIRUVATO CINASE ACTIVATORS FOR USE IN THERAPY
FIELD OF THE INVENTION
The invention relates to methods for increasing the life of the red blood cells (RBC) that need it.
/ BACKGROUND D ^ S
THE INVENTION
This request claims priority from the USSN
61 / 482,171, filed on May 3, 2011, which is fully incorporated herein by this reference.
Pyruvate kinase deficiency (PKD) is one of the most common enzyme defects in erythrocytes in humans due to autosomal recessive mutations of the PKLR gene (Zanella, A., et al., Br J Haematol 2005, 130 (1 ), 11-25). It is also the most frequent enzyme mutation in the central and only second glycolytic pathway of glucose-6 phosphate dehydrogenase (G6PD) deficiency (Kedar, P., et al., Clin Genet 2009, 75 (2), 157-62 ) of the derivation of hexose monophosphate.
Human erythrocytes are unique in that they do not form a nucleus when mature. Immature erythrocytes have nuclei but during early erythropoiesis before becoming circulating reticulocytes they extrude the nuclei, as well as other organelles such as mitochondria, endoplasmic reticulum and Golgi apparatus, to make room for hemoglobin that carries oxygen. As a result of not having mitochondria, mature red blood cells do not use the oxygen they carry to synthesize adenosine triphosphate (ATP) economically as other normal differentiated cells do. In contrast, red blood cells rely entirely on anaerobic glycolysis to cycle nicotinamide adenine dinucleotide (NAD +) and to make ATP, an essential energy source widely used to drive ATPase-dependent K + / Na + and Ca2 + pumps, to maintain integrity. and flexibility of the cell membrane as they navigate through the blood vessels. In PKD disorder, two main distinctive metabolic abnormalities are the elimination of ATP and the concomitant increase of 2,3-diphosphoglycerate consistent with the accumulation of higher glycolytic intermediates. In addition, one of the consequences of reducing the level of pyruvate and ATP is the lower level of lactate leading to an inability to regenerate NAD + through lactate dehydrogenase for additional use in glycolysis. The lack of ATP alters the gradient of cations through the red blood cell membrane, causing the loss of potassium and water, which causes dehydration, contraction and cellular creation and leads to premature destruction and reduced life time of red blood cells (RBC). Such defective RBCs are destroyed in the spleen and the rate of excessive hemolysis in the spleen leads to the manifestation of hemolytic anemia. The exact mechanism by which PKD sequesters newly mature RBCs in the spleen to effectively reduce the overall half-lives of circulating RBCs is still unclear, but recent studies suggest that metabolic deregulation affects not only cell survival but also the process. of maturation which results in an ineffective erythropoiesis (Aizawa, S. et al., Exp Hematol 2005, 33 (11), 1292-8).
Pyruvate kinase catalyzes the transfer of a phosphoryl group from osp oenolpyruvate (PEP) to ADP, which provides a pyruvate molecule and an ATP molecule. The enzyme has an absolute requirement for Mg2 + and K + cations to trigger catalysis. PK works as the last critical step in glycolysis because it is an essentially irreversible reaction in physiological conditions. In addition to its role in synthesizing one of the two ATP molecules of glucose metabolism in pyruvate, pyruvate kinase is also an important regulator of cellular metabolism. It controls the flow of carbon in the lower glycolysis to provide intermediates of key metabolites to feed biosynthetic processes, such as the pentose-phosphate pathway among others, to maintain a healthy cellular metabolism. Due to these critical functions, pyruvate kinase is firmly controlled both at the level of gene expression and allosteric enzyme. In mammals, fully activated pyruvate kinase exists as a tetrameric enzyme. Four different isozymes (Mi, M2, L and R) are expressed from two separate genes. The erythrocyte specific PKR isozyme is expressed from the PKLR gene (L gene) located on the lq21 chromosome. This same gene also encodes the PKL isozyme, which is predominantly expressed in the liver. PKLR consists of 12 exons where exon 1 is erythroid specific while exon 2 is liver specific. The other two mammalian isozymes PKM1 and PKM2 are produced by the PKM gene (M gene) by alternative splicing events controlled by hnRNP proteins. The PKM2 isozyme is expressed in fetal tissues and in adult proliferation cells, such as cancer cells. Both PKR and PKM2 are in fact expressed in proeritroblasts. However, after erythroid differentiation and maturation, PKM2 gradually decreases in expression and is progressively replaced by PKR in mature erythrocytes.
Clinically, hereditary PKR deficiency disorder manifests as non-spherocytic hemolytic anemia. The clinical severity of this disorder ranges from unobservable symptoms in fully compensated hemolysis to potentially fatal severe anemia that requires chronic transfusions and / or splenectomy to early development or during physiological stress or serious infections. The most affected individuals who are asymptomatic, paradoxically due to the improved oxygen transfer capacity, do not require any treatment. However, for some of the most serious cases, although they are extremely rare compared to the population with an estimated prevalence of 51 per million (Beutler, E. Blood 2000, 95 (11), 3585-8), no treatment is available to modify the disease for these patients other than palliative care (Tavazzi, D. et al., Pediatr Ann 2008, 37 (5), 303-10). These patients with hereditary non-spherocytic hemolytic anemia (HNSHA) have a clear unmet medical need.
Heterogeneous genetic mutations in PKR lead to deregulation of their catalytic activity. From the initial cloning of PKR and the Thr384> Met report of a single mutation point associated with a patient with HNSHA (Kanno, H. et al., Proc Nati Acad Sci USA 1991, 88 (18), 8218-21) , there are currently almost 200 different mutations reported associated with this disease reported worldwide (Zanella, A. et al., Br J Haematol 2005, 130 (1), 11-25; Redar, P., et al., Clin Genet 2009, 75 (2), 157-62; Fermo, E. et al., Br J Haematol 2005, 129 (6), 839-46; Pissard, S. et al., Br J Haematol 2006, 133 (6), 683-9). Although these mutations represent genetic lesions of wide range that include abnormalities of elimination and transcription or translation, by far the most common type of mutation with change of direction in the coding region that in one way or another affect the residues conserved within domains that are structurally important for the optimal catalytic function of PKR. The pattern of mutation prevalence seems to be irregularly distributed to specific ethnic settings. For example, the most frequent codon substitutions reported for patients in North America and Europe appear to be Arg486> Trp and Arg510> Gln, while mutations Arg479> His, Arg490> Trp and Asp331> Gly were found more frequently in Asian patients (Kedar, P., et al., Clin Genet 2009, 75 (2), 1577
BRIEF DESCRIPTION OF THE INVENTION
The present invention provides a method for increasing the life of the red blood cells (RBC) that need it comprising contacting blood with an effective amount of (1) a compound described herein or a pharmaceutically acceptable salt thereof; (2) a composition comprising a compound described herein or a salt thereof and a carrier; or (3) a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The present invention further provides a method for regulating the levels of 2,3-diphosphoglycerate in blood that needs it comprising contacting blood with an effective amount of (1) a compound described herein or a pharmaceutically acceptable salt thereof; (2) a composition comprising a compound described herein or a salt thereof and a carrier; or (3) a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The present invention also provides a method for treating hereditary non-spherocytic hemolytic anemia which comprises administering to a subject in need thereof a therapeutically effective amount of (1) a compound described herein or a pharmaceutically acceptable salt thereof, (2) a composition. Pharmaceutical comprising a compound described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The present invention also provides a method for treating sickle cell anemia comprising administering to a subject in need thereof a therapeutically effective amount of (1) a compound described herein or a pharmaceutically acceptable salt thereof, (2) a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The present invention also provides a method for treating hemolytic anemia (eg, chronic hemolytic anemia caused by phosphoglycerate kinase deficiency, Blood Cells Mol Dis, 2011; 46 (3): 206) comprising administering to a subject in need a therapeutically effective amount of (1) a compound described herein or a pharmaceutically acceptable salt thereof, (2) a pharmaceutical composition comprising a compound described in the present or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The present invention also provides a method of treating thalassemia (e.g., beta-thalassemia), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia, (e.g., congenital anemias ( for example, enzymopathies)) or anemia of chronic diseases comprising administering to a subject in need a therapeutically effective amount of (1) a compound described herein or a pharmaceutically acceptable salt thereof, (2) a pharmaceutical composition comprising a compound described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The present invention also provides a method for treating diseases or conditions that are associated with higher levels of 2,3-diphosphoglycerate (e.g., liver diseases (Am J Gastroenterol, 1987; 82 (12): 1283) and Parkinson (J. Neurol, Neurosurg, and Psychiatry 1976,39: 952) which comprises administering to a subject in need a therapeutically effective amount of (1) a compound described herein or a pharmaceutically acceptable salt thereof, (2) a pharmaceutical composition that it comprises a compound described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
The compounds and compositions described herein are activators of PKR mimics that have lower activities compared to those of the wild type, and are therefore useful for the methods of the present invention. Such mutations in PKR can affect enzyme activity (catalytic efficiency), regulatory properties (modulation by fructose bisphosphate (FBP) / ATP) and / or the thermostability of the enzyme. Examples of such mutations are described in Valentini et al, JBC 2002. Some examples of mutants that are activated by the compounds described herein include G332S, G364D, T384M, G37E, R479H, R479K, R486W, R532W, R510Q and R490W . Without being limited by theory, the compounds described herein affect the activities of PKR mutants by activating PKR mutants that do not respond to FBP, restoring thermostability to mutants with decreased stability, or restoring catalytic efficiency to defective mutants. The activation activity of the present compounds against PKR mutants can be evaluated following a method described in Example 1. The compounds described herein are also wild type PKR activators.
In one embodiment, to increase the life of the red blood cells, a pharmaceutical compound, composition or composition described herein is added directly to whole blood cells or extracorporeal red blood cell concentrates or provided to the subject (eg, the patient) directly (for example, by administration ip, iv, im, oral, inhalation (aerosol administration), transdermal, sublingual and other routes of administration). Without being limited by theory, the compounds described herein increase the life of RBCs, thus counteracting the aging of stored blood, affecting the rate of 2,3-DPG release from the blood. A decrease in the level of 2,3-DPG concentration includes a shift to the left of the hemoglobin and oxygen dissociation curve and changes the allosteric equilibrium to R, or oxygen state, thus producing a therapeutic inhibition of polymerization. intracellular underlying sickle cell disease increasing oxygen affinity due to depletion of 2,3-DPG, thus stabilizing the more soluble oxyhemoglobin. Accordingly, in one embodiment, the compounds and pharmaceutical compositions described herein are useful as antidrepanocytosis agents. In another embodiment, to regulate 2,3-diphosphoglycerate, a pharmaceutical compound, composition or composition described herein is added directly to whole blood cells or extracorporeal red blood cell concentrates or provided to the subject (eg, to the patient) directly ( for example, by administration
ip, iv, im, oral, inhalation (aerosol administration), transdermal, sublingual and other routes of administration).
In one embodiment, a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt of formula (I) is provided:
<img file="MX367387B_D0002.tif" />
(I where:
W, X, Y and Z are each independently selected from CH or N;
D and DI are independently selected from a link or NRb;
A is optionally substituted aryl or optionally substituted heteroaryl;
L is a bond, -C (O) -, - (CRcRc) m-, -0C (0) -, - (CRcRc) m0C (0) -, - (CRcRc) mC (0) -, -NRbC (S ) - or -NRbC (O) - (where the point of attachment to R1 is on the left side);
R1 is selected from alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; each of which is substituted with 0-5 occurrences of Rd;
each R3 is independently selected from halo, haloalkyl, alkyl, hydroxyl and -ORa, or two adjacent R3, together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl; each Ra is independently selected from alkyl, acyl, hydroxyalkyl and haloalkyl;
each Rb is independently selected from hydrogen and alkyl;
each Re is independently selected from hydrogen, halo, alkyl, alkoxy and haloalkoxy, or two Re, together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl;
each Rd is independently selected from halo, haloalkyl, haloalkoxy, alkyl, alkynyl, nitro, cyano, hydroxyl, -C (O) Ra, -0C (O) Ra, -C (O) ORa, -SRa, -NRaRb and - ORa, or two Rd, together with the carbon atom to which they are attached form an optionally substituted heterocyclyl;
n is 0, 1 or 2;
m is 1, 2 or 3;
h is 0, 1, 2; and g is 0, 1 or 2.
DETAILED DESCRIPTION OF THE INVENTION
Examples of compounds are found in Table 1.
<td></td><td>% A «t. R510Q</td><td>% Act. R532W</td><td>% Act. T384W</td><td>% Aa.wr</td><td>pkrwt ACSO (μΜ)</td><td>PKR R510Q ^ C50 (μΜ)</td><td>»KRR532W AC5O || 1M)</td><td>> KRT384W ACM (HM)</td><td>PKRG3325 ftC50 (| xM)</td><td>PKR G364C Α £ 50 (μΜ)</td><td>PKR G97E AC50 (μΜ)</td><td>PKRR479H AC50 (txM)</td>
<td></td><td>B</td><td>B</td><td>B</td><td> 0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>OR τ Γ <sup>N</sup> ]] Π ¿R ^ ^ r¿</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>; or << - Ό LjL% * ° ¡s U ^ '¿P</td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td>B</td><td>and</td><td></td><td>DC</td><td>BB</td><td> 88</td><td></td><td>DC</td><td></td><td>AA</td>
<td>cloW</td><td>B</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td>AA</td><td>BB</td><td>AA</td><td>AA</td><td>BB</td><td>BB</td><td>•DC</td><td>AA</td>
<td></td><td>and</td><td> 8</td><td>and</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> /0^0^0^-¾</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td>AA</td><td>AA</td><td>AA</td><td></td><td>B8</td><td></td><td>AA</td>
<td><sub>c</sub>. <rOyCr ^%</td><td> 8</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.xro ^ cr '^</td><td> 8.</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td> —</td><td></td><td></td><td></td><td></td>
<td>ίχο<sub>τ</sub>σ<sup>β</sup>Α</td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td>BB</td><td>AA</td><td>AA</td><td>AA</td><td>BB</td><td></td><td>AA</td>
<td>xo<sup>b</sup>7¿2)</td><td>B</td><td>B</td><td> 8</td><td>B</td><td>AA</td><td>AA</td><td>AA</td><td>AA</td><td>DC</td><td>BB</td><td></td><td>AA</td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>οςο / Λ'ίό ch<sub>3</sub> 0</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>φΌ ^ ί)</td><td>B:</td><td>B</td><td>B:</td><td>and</td><td>AA</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> *5?^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>,and</td><td>AÁ</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td></td><td>B.</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td>. ^ Ojü'íS</td><td>B<sup>J</sup></td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CCOjCt ^ Η £ '°</td><td>B</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>B8</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td>-χςρ / τΆ</td><td>B</td><td>B</td><td>B</td><td>B</td><td>8B</td><td>DC</td><td>AA</td><td>BB</td><td></td><td></td><td></td><td></td>
<td>. ^ OjCóbob</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td>AA</td><td>AA</td><td></td><td></td><td>I know</td><td></td><td>AA</td>
<td>β * Ύ ^ ι <sub>Λ Λ</sub></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>QΦ</td><td>B</td><td>B</td><td>.B</td><td>P.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ζ / ΟγΟ ^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>φ ^ Ογίχ ^ Ά</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ΟγΟ ^ ί)</td><td>TO</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Χ<sub>α</sub>, ΡγΜ ° ou</td><td>B</td><td>B</td><td>B.</td><td>B</td><td></td><td><X</td><td></td><td>BB</td><td>AA</td><td></td><td></td><td>BB</td>
<td></td><td>B</td><td>B</td><td>B</td><td>TO</td><td>AA</td><td>BB</td><td>AA</td><td>AA</td><td>AA</td><td>BB</td><td></td><td>AA</td>
<td></td><td>B.</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0^0^<sup>8</sup>½</td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>, χ / Ογςτ '' ^ ·</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>φίο ^ σ ^</td><td>B</td><td>B</td><td>B '</td><td>s</td><td></td><td></td><td></td><td></td><td>AA</td><td>B8</td><td></td><td>AA</td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td>DC</td><td>DC</td><td></td><td></td><td>EC</td><td></td><td>DC</td>
<td><sup>Μ</sup>Ρ</td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>(/ ο / ϊ ^</td><td> 8</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ OyCrWi</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>. ^ Χΐ, χ<sub>ο</sub>^^</td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'^ r ^ XOyCr' '^</td><td>TO</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>kyj ^</td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>crOyOí ^ i</td><td>B</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cro ^ I heard ”^</td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B '</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>-μΟ ^ ΟγΟ '^</td><td>B</td><td> 8</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or<sup>and</sup>Ti o ^ o to</td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td> 8</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ OyO ^</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'ύΎ' ΟιΊ% ° * ^ ajf] <sup>0</sup> N '<sup>J</sup>*Y</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>g »» «- '^<sup>C</sup>OyO '? Í ^ “</td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>X OU, or</td><td>B</td><td>B</td><td> 8</td><td> 0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>° Ρ<sub>Ύ</sub>Ο ^ ° ~ · o</td><td>TO</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>QHj</td><td>Β</td><td>Β</td><td>Β</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>___ Γ * HC / - ( OR<sub>N</sub>^ <^ ¿-> 1 ^ Ó '' □</td><td>Β</td><td>Β</td><td> 0</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^0^3^</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ J> “· ^ ° - £> <rt XX r “' ^ ΟγΟΓΛ ^</td><td>Β</td><td>Β</td><td> 8</td><td> 6</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Γ '</td><td>Α</td><td>Β</td><td>Β</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> '<sup>ζΧ</sup>»<sup>Α</sup>Ο<sub>ϊ</sub>0'Ά</td><td>Β</td><td>Β</td><td>Β</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'^ • ΛΟγΟτΆ</td><td>Β</td><td>Β</td><td>and</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ο ^ σΆ</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ΰ ^ * · Ϊ ^ Ι</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td>DC</td><td> 06</td><td>ΒΒ</td><td>ΒΒ</td><td>DC</td><td></td><td>ΒΒ</td>
<td> ^,¾¼¾</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> -¾^¾</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td>DC</td><td>ΑΑ</td><td>ΒΒ</td><td>DC</td><td>DC</td><td>DC</td><td>ΒΒ</td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0^0¼^</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>0- / 3¼ ^ ¼ you ° '</td><td>Β</td><td> 3</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0^0%^</td><td>Β</td><td>Β</td><td>Β</td><td>ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0/¼¾</td><td>Α</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.Λ ^ 'ΟγΟ' ^</td><td>Α</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^0^-¾</td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>σ- ^ ΟγΟΓ ^</td><td>Α</td><td>Β</td><td>Β</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td> 0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Η, ϋ __</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>OR</td><td>TO</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>WjC cto ^ SS</td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>κ, ς c ^ O ^ íó</td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>α: ^ · ρΑ, χχ k ^ NA ^ J o 'a li-tf</td><td>TO</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ΟΑ u η <sup>k</sup> Ο ^> ίά-</td><td>B</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ζ / ΟγΟ ^^</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CHa- I HEARD <or 0 ^ 0 * -<sup>N</sup></td><td>TO</td><td>B</td><td>TO</td><td>TO</td><td>AA</td><td>B0</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td><OÓ '<sup>to</sup></td><td>B</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>(XOO ^ ft or</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>C</td><td> 8</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td>DC</td><td>DC</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>b</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^0/7’’^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td>DC</td><td></td><td>EC</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ H,</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B ·</td><td> 2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ¿Y.-a</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>3 <i<sub>s</sub>xy''ft</td><td>TO</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 36^^¾</td><td>TO</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>“°> Ό /> ^</td><td>TO</td><td>B</td><td>B</td><td>S</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>g</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ • 0 ^ 0 O</td><td>B</td><td>B</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>w ^ oVj O ' <sup>OR</sup> k ^ yX ^ Nv ^ J</td><td>TO</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>W ^</td><td>TO</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>£ Η<sub>Λ</sub> Ϊ<sup>Η</sup>* ^ OyO ^ O</td><td>TO</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><C / -kw? ».A; ^ v ^ Γ ^ 'ϊ' ^ Τ ''<sup>6</sup>! ° ° U »X, n ^> Ñ ^ J</td><td>B</td><td>B</td><td>B</td><td> £</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>2 ”\ s_z<sup>CH</sup>O ^. ^ 0X1</td><td>B</td><td>B</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>á ^ O ^ O ^ O</td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ' '<sup>cx</sup>or<sub>T</sub>cr'x%</td><td>B</td><td>TO</td><td>B</td><td> 0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> Í<sup>H</sup>*</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.. ^ XTOyCr / íó</td><td>B</td><td> 8</td><td>B</td><td>B</td><td>DC</td><td></td><td>8B</td><td></td><td></td><td></td><td></td><td></td>
<td><sup>C</sup><sub>?</sub>XTO / T ^ ft)</td><td>B</td><td>B</td><td>B</td><td>B</td><td>BB</td><td>DC</td><td>BB</td><td>BB</td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td> 0</td><td></td><td></td><td></td><td> 1</td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>¿H¿-</td><td>TO</td><td> 8</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>X. I</td><td>TO</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ jOO.jXr ^</td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td>AA</td><td>AA</td><td>AA</td><td></td><td>BB</td><td></td><td>AA</td>
<td></td><td>B</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ jOTOyOr ^.</td><td>B</td><td>B</td><td>B</td><td>B</td><td>DC</td><td> 02</td><td>DC</td><td>DC</td><td></td><td></td><td></td><td></td>
<td>¿Ro ^ 'ft</td><td>B</td><td>B</td><td>B</td><td>and</td><td>BB</td><td>DC</td><td>BB</td><td>BB</td><td></td><td></td><td></td><td></td>
<td>¿COy <r<sup>x</sup>ft></td><td>B</td><td> 8</td><td>B</td><td>and</td><td>AA</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td> 8</td><td>B</td><td>AA</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td>¿CO / r ^ ft</td><td>B</td><td>B</td><td> 8</td><td>B</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td> 8</td><td>B</td><td>B</td><td>AA</td><td> □0</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td> 2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 3</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>and</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td> 8</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>O ^ OyCr ^ ft</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>¿RO ^ "<sup>?</sup>-'ftj</td><td>B</td><td> 8</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ττΟγσ ^</td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>: χγό / ϊ ^</td><td>TO</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'^ ¿Ro ^ jCri ^ J)</td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 3</td><td>B</td><td>B</td><td>B</td><td>DC</td><td>GC</td><td>DC</td><td>DC</td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td>DC</td><td>DC</td><td>BB</td><td></td><td></td><td></td><td></td><td></td>
<td>cmj α</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>σ</sup>'φτ'ο<sub>τ</sub>α '^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td>DC</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ '/ Ογότ ^ δ)</td><td>B</td><td>B</td><td>B</td><td> 0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ο '^ γ ^ γ<sup><</sup>τ * Ίι ©, or ¿r ^</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sub>or</sub>.ch ^<sub>n</sub>X_ ^ <sub>or or</sub> or Ó · ^ ^ Οφ,</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>xoVv, L ^ UH »</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>¿P ^ os</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^0^-¾</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ao KC · .Λ-ο '*'</td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ O<sup>X</sup>CL ^<sub>0l</sub></td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> TO</td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ΛΗγζ-χ ,, - ^ ίΤη. q ^<sub>or </sub>¿T<sup>J</sup></td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>(/ 'V'jrS' ^ il A? F <sub>F </sub>aJ-v ^ irVr ^ 'L ^ * α <* ·> * · *</td><td>B</td><td>B</td><td>β</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Ó-'V ^ '^ · * ^ O¿> or ^ ix- ·</td><td> 5</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.ch ^<sub>n</sub>X ^ j ^ q, ^> Oa</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^<sup>1</sup>°¾</td><td>B</td><td>Θ</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>xjl</td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cPo ^ ft</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td> 02</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>o- ° yVx1A<sup>p</sup>: i Λ-<sup>ν</sup>'> ü γ></td><td>B</td><td>B</td><td>and</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td rowspan="15"> 5 10 15 20</td><td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ά - .. m-</td><td>B</td><td> 8</td><td>B</td><td>to</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td> 8</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>α</sup>δ ^^ 2)</td><td>B</td><td>B</td><td>: B</td><td>and</td><td>6B</td><td>GC</td><td>DC</td><td>DC</td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Uh,</td><td>B</td><td>B</td><td>B</td><td>and</td><td>AA</td><td>BB</td><td>AA</td><td></td><td></td><td></td><td></td><td></td>
<td>.ΗηΟ - '^ αΜ *</td><td>TO</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ΓΌγΟ · ^.</td><td>B</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>DC</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td>φτΟγϋ '^ íf</td><td>B</td><td>B</td><td>B</td><td> 3</td><td>BB</td><td>GC</td><td>AA</td><td>BB</td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>., ^ χτο ^ σ ^</td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>θνΟγΟ '' '^</td><td>B</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>BB</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>AND</td><td>.BB</td><td>DC</td><td>BB</td><td>BB</td><td></td><td></td><td></td><td></td>
<td>. ^^ cro ^ 'ft</td><td>B</td><td>B</td><td>B:</td><td>AND</td><td>DC</td><td>GC</td><td>BB</td><td>BB</td><td></td><td></td><td></td><td></td>
<td>íX'O ^ jO'-¿m H</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td> .</td><td></td><td></td><td></td><td></td>
<td>¿Χρ ^ + íi</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td>DC</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>δ</td><td>DC</td><td>DC</td><td>BB</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.. ^ rroprí ^</td><td>B</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ςςΟγΟτ ^</td><td>B</td><td>B</td><td>B</td><td>and</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td>B</td><td>and</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>,</sup>'CQ3<sub>r</sub>C '' ^</td><td> 8</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td><sub>R</sub>RXi<sub>T</sub>C ^ -ft</td><td> 3</td><td>B</td><td>C</td><td>B</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 3</td><td>B</td><td>B</td><td>S</td><td>AA</td><td>DC</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>qpo ^ 'íó</td><td>B</td><td>B</td><td>B</td><td> □</td><td>AA</td><td>AA</td><td></td><td>AA</td><td></td><td></td><td></td><td></td>
<td><sub>K</sub>4pp / y ° * s</td><td>B</td><td>B</td><td>B</td><td> 5</td><td>AA</td><td>BB</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td>«Pw / Pft</td><td>S</td><td>B</td><td>B</td><td>B</td><td></td><td>DC</td><td>AA</td><td></td><td></td><td></td><td></td><td></td>
<td>cgo / ^ - íi</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>OCpprrfl</td><td>B</td><td>B</td><td>TO</td><td> 8</td><td>AA</td><td>BB</td><td>AA</td><td>AÁ</td><td></td><td></td><td></td><td></td>
<td>XpOp - '^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td> 1</td><td></td><td></td><td></td><td></td>
<td>Λ </td><td>B</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>DC</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>-to</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ OCOyCr'-ft</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>. ^ XTOyjCr ^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ crOyO ^</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 000^^¾</td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>..c ^ OyC ^</td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>DC</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td>Λ ~ ^ ~ «<sub>:</sub>A ΙνγΧ '° M</td><td> &</td><td> 8</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>r<sup>3</sup>^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>xo ^ xy ^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>. ^ J ^ OyCr ^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td>g</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>. ^ ίςτΟγΟρ ·· ®)</td><td>TO</td><td>TO</td><td>TO</td><td> 3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ςτα ^ α '^</td><td>TO</td><td>TO</td><td>TO</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 9^0/^¾</td><td>TO</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.pxft</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^0/5^-¾</td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CrOyCr ^</td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ¢^0^-¾</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>¢ ^ 3 /} ¼¾ T</td><td>B</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td> 8</td><td></td><td>BB</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 6</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0¾^^¾</td><td> 8</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>u ° '° Γ * ι cyo ^ Crnó</td><td>to</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^0^0-<sup>8</sup>¾</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ys + íú</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td> 8</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'%#to</td><td> 8</td><td>TO</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'^' r ^ o ^ cr ^</td><td>B</td><td>TO</td><td> .3</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 3</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td> &·</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 3</td><td>TO</td><td> 3</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^^ O-jXxM?)</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sub>F</sub>j9n /> o '£ Jj</td><td>B</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>BB</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td>Cro ^^</td><td>B</td><td>B</td><td> 6</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ C ^ er '-' a</td><td>B</td><td>TO</td><td> 3</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>w ·· ^</td><td>B</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CH *</td><td>B</td><td>TO</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>gc ^ -ft</td><td>B</td><td>TO</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ χ \ σ ^ δ</td><td>B</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>. ^ - F '·' ^ 'vH,</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>0-0.0 + ¾ K, C</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B ··</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>«.¿Ρςο ^ σ ^</td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>κ, ^ ιχο ^ σ ^</td><td>B</td><td>B</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>jro ^</td><td>B</td><td>B</td><td>B</td><td>B '</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>χςα ^ '^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td> 8<sup>:</sup></td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cx-O / ^^ íi</td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>liH,</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>H £ '</td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ cOXr ^ ft C ^<sup>F</sup> i Ci</td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 0</td><td>S</td><td> 3</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>OH</td><td>B</td><td>B</td><td> 3</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Cf</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td>DC</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>0-0 ^ 0 ^ Cl 'Gt</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> <<>#·’*</td><td>B<sup>:</sup></td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ OyO-Xb</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^-0^<sup>1</sup>¾</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>0-O / ^ ft \ / ~ CH,</td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CfOrCr '.' Ft. /</td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CH,</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>TO</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Α</td><td>Α</td><td>Β</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Α</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Α</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>Ία</sup>ο<sub>τ</sub>σ ^ ί?)</td><td>Β</td><td>Β</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>rPo ^ yPo</td><td>Α</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>“^^ ΟγΟ<sup>8</sup>^</td><td>Α</td><td>Α</td><td>Α</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ΟγΟ ^</td><td>Β<sup>:</sup></td><td>Β</td><td>Β</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>ό; σ</sup>Ό<sub>ϊ</sub>α ^</td><td>Α</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>C ^ Ov ^ CH » ^ ΟγΟ ^ Ι</td><td>Β</td><td>Β</td><td>Β</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0-0<sup>1</sup>¾</td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ -ΟγΟ ^</td><td>Β</td><td>Α</td><td>Β</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> -^0^--¾</td><td>Β</td><td>Α</td><td>Β</td><td>δ</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td> .3</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>¿OyS '^ ft</td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ Qy¿X''ftl</td><td>B</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><A} and (S ^ ft</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><^ Oy <5 ^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ay¿r''ft</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'^^ OyC / X ^ I</td><td>B</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ OyC ^ ft</td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>F</sup>^ OyO<sup>to</sup>TO</td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>XX to XX Γ ^ Γ 'Λ T * il °' °</td><td>B</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ÍXyCr ^</td><td>B.</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>B</td><td>ÁA</td><td>BB</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td> 8</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ΟγΛ ^</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>, ^ φ ^ Ογότ'Λ</td><td>B</td><td>B</td><td>TO</td><td>Ξ</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>c / o ^ WS)</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></ o and W?)</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ CCOyír ^ ftii</td><td>B</td><td>B</td><td>B</td><td>and</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>, -ΧΧΟ ^ Ά</td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'Ίφτο ^^ / δ</td><td>B</td><td>B</td><td> 8</td><td>B</td><td>AA</td><td>BB</td><td>AA</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Α</td><td> 0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ΓΟγί ^ 'Λ</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ¿ΠΟγδ ^</td><td>Β</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>c</sup> Ro ^ W?)</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ¢¢0^<sup>1</sup>^¾</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ςτο / χ ^</td><td>Β '</td><td>Β</td><td> .3</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>φςο / ϊ '^)</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td> .8</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ίχο ^ Ά</td><td>Β</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CU</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td>ΑΑ</td><td>DC</td><td>ΑΑ</td><td>ΑΑ</td><td></td><td> 88</td><td></td><td>ΑΑ</td>
<td>^ Í ^ OyCrVft</td><td>Β</td><td> 8</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Β</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>5 ^ Ογί5Ά</td><td>Β</td><td>to</td><td>Β</td><td>Β</td><td>ΑΑ</td><td>3Β</td><td>ΑΑ</td><td>ΑΑ</td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^^ ΟγΛΆ</td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CÍOyÓ '^ S</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>β</td><td>Α</td><td>β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> '<sup>ί</sup>Μο.<sub>ί</sub>ώ'Ά</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Α</td><td>Β</td><td>Β</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ζ / ο ^ Ά</td><td>β</td><td>Β</td><td>Α</td><td>Ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Α</td><td>Α</td><td>Α</td><td>Ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td> 3</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.χχα / χΛ®</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'Tjro ^ xxX?)</td><td>B</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.jjrOyQX?)</td><td>B.</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>--μχΟγα'Α</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ,^0.^0¼¾</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cxo ^ ct ^ ft</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>xto ^^ Qj</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ί ^ ΟγΟί / ^)</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> .10^0^0¼¾</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>φςΟγΟ & β)</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ai**! ^ O / ^ AU</td><td>B</td><td>B</td><td>S</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>οηο ^ χζ)</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>R</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td> 8</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ o / S '^ S</td><td>B</td><td> 8</td><td>B</td><td> 3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td> 8</td><td>AA</td><td>DC</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>B</td><td>BB</td><td>DC</td><td>BB</td><td> 88</td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td> 8</td><td>B</td><td> 8</td><td>DC</td><td>oz</td><td>DC</td><td>DC</td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>r * «jíjl C></td><td>B</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>0 — ο ^ ςτΆ</td><td>B</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ HEARD '^</td><td>B</td><td>TO</td><td>S</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0¾^^¾</td><td>B</td><td> 8</td><td>B</td><td>1 B</td><td></td><td></td><td></td><td> 1</td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>S</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B ·</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^¾<sup>3 </sup>cp<sub>5</sub></td><td>B</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>M</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or \\ or> 2)</td><td>B</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>w</sup>'^ Aq «5τ-ί2)' J</td><td>TO</td><td>TO</td><td>B</td><td> 3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Q ^ C / X ^ íft</td><td>B</td><td>B</td><td>B</td><td>δ</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td> 8</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td> 8</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>¢ ^ 0 /% ¾ Q</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0^0^^¾</td><td> 8</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>S ^ o / y ^</td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Fu / tf ^ h YH f Y CTO ^ O'-íGD</td><td>B</td><td> 8</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CIO / ^ '- ftj</td><td>B</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>BB</td><td></td><td></td><td></td><td>DC</td><td></td><td>AA</td>
<td><sup>W</sup>'CH,</td><td>B</td><td>B</td><td>B</td><td>s</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> -^0¼^^¾</td><td> 8</td><td>to</td><td>B</td><td>B</td><td>BB</td><td>DC</td><td>BB</td><td></td><td></td><td></td><td></td><td></td>
<td> 9^0.^=^¾</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ςτο / χϊΛ</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>?</sup> “ <sup>¿</sup>'CH,</td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>«ΡτορξΡ / δ</td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.JXOyXjr '^</td><td>B</td><td>B</td><td>B.</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>me and</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.iXQy ^ 'íi</td><td>B</td><td>TO</td><td> 8:</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ycypb</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^0^°<sup>9</sup>¾</td><td>B</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>c</sup>xro<sub>T</sub>p ^ ft}</td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>(ΡΟγΟ ° '° O<sup>OR</sup> 'CH,</td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CH,</td><td>B</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td> 8</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.xro ^ ft</td><td>B</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Ηί<sub>ο </sub>tro ^^ j</td><td>TO</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>H, C ím / Mb</td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'ixa ^ íb</td><td>faith</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>-XCO ^ íJ?)</td><td>B</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CCO / & $)</td><td>B</td><td>B</td><td>TO</td><td> 5</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>to</sup>% VO ^ V¿%</td><td>B</td><td>TO</td><td>B</td><td> 9</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>& ο / ι ^</td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cjo / x ^</td><td>TO</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td> •</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> £^0^0¾<sup>5</sup>¾</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>íJ ^ OyCt ^</td><td>B</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>_JL i, -Ok , ίΟιΟ., ΧΧ ^ '^ Ο l ¿H.</td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B.</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>° Ό<sup>Λ</sup>Ό<sub>ϊ</sub>α ^ · 5)</td><td>B</td><td> 3</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'χ / Ό-jXX ^</td><td> '0</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>OjOyCX ^ 'í)</td><td>Β</td><td>Α</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0/0/¾¾</td><td>β</td><td>Β</td><td>β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>.Β-</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>eXXO / x ^ ft</td><td>Β</td><td>Β</td><td>.Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>. ^ rOyOt ^ ft</td><td>Β</td><td>θ</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'γρ ^ Φ</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sub>C</sub>XXO ^ 45</td><td>Β</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>° χ? Οχτ> -ίέ » A ¿.Η,</td><td> 8</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ο ^ α / χΧδ</td><td>Β</td><td>Β</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.xro ^ ftj</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Η £ Mrcy ^ ñ</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Η, 6áxiyctói</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td>ΑΑ</td><td>ΒΒ</td><td>ÁA</td><td>ΑΑ</td><td></td><td>ΒΒ</td><td></td><td>ΑΑ</td>
<td>CCO ^ Cc ^ S)</td><td>Α</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td><sup>:</sup>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Or h</td><td>B</td><td>TO</td><td>; -B<sub>:</sub></td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><τοχ / ό</td><td>and</td><td>B</td><td>and</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>¿K, Ha δ ¿H »</td><td>TO</td><td>TO</td><td>TO</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'ψΧλγΌί'Λ</td><td>AND</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ Ο / Ι> £ 5</td><td>TO</td><td>TO</td><td>.B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'¿Ταχ / ό</td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>crOyC ^ ft</td><td>B</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td>, χχο ^ α ^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>οςΟγΟ ^</td><td>Β</td><td>Β</td><td>δ</td><td>Β</td><td>ÁA</td><td>ΒΒ</td><td>ΑΑ</td><td>ΑΑ</td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>δ</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ÜH,</td><td>Β</td><td>Β</td><td>δ</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>.χτο ^ χχ'Λ</td><td>Α</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ή ^ ΟφΟφίδ</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>VO ^ A</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Α</td><td>Α</td><td>δ</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ÍXO ^ Jíft</td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ίΧΟγ © ^</td><td>Α</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>crn ^ ccWi)</td><td>Α</td><td>Α</td><td>δ</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>g</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>, B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'CH,</td><td>B</td><td>B</td><td>B</td><td>and</td><td>AA</td><td>BB</td><td>AA</td><td></td><td></td><td></td><td></td><td></td>
<td>'CRj</td><td>B</td><td>B</td><td>B</td><td> 5</td><td>BB</td><td></td><td>BB</td><td></td><td></td><td></td><td></td><td></td>
<td>cro ^ ft</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Y ^ Oypr ^ ft</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ÍXO- ^ Í)</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>φπο ^ Α</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>c ^ O ^ Pi</td><td>TO</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>νΧτο, ^ ΛΑ</td><td>TO</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cro ^ Píí</td><td>B</td><td>B</td><td>B</td><td>. and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><XO. ^ DS</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>¿Ro ^ y ^</td><td>B</td><td> 0</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sub>F</sub>yCmy'A</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><xoyAftj</td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> °-°<sup>X</sup>O ^ j3<sup>4</sup>?^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>€ Γ '<sup>Χ</sup>Ο ^ Ά</td><td>B</td><td>B</td><td><sup>:</sup>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>AND</td><td>EC</td><td></td><td>DC</td><td>DC</td><td></td><td></td><td></td><td></td>
<td>θ ^ ΟγΟ · '^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^½^%¾</td><td>B</td><td>B</td><td>B</td><td> 8</td><td>AA</td><td>BB</td><td>AA</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td>AA</td><td></td><td></td><td></td><td>BB</td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> -^0^¾¾</td><td>B.</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>S \ v ^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cro ^ Cr<sup>8</sup>^?)</td><td>B</td><td>B</td><td>B</td><td>, B</td><td>AA</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td>CW ^ or ^ ift</td><td>B</td><td>B</td><td>B</td><td>B</td><td>AA</td><td>DC</td><td>AA</td><td>BB</td><td>BB</td><td>BB</td><td>DC</td><td>AA</td>
<td>ίΧΟγά ^</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ΧίΓΟτΡ '^ δ * “XH,</td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ xro ^ rWjj * ^ Cii,</td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'XTOy ^ ftl</td><td>TO</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>9 Hey,</td><td>TO</td><td>TO</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Ij £ <% ο ^ ΟτΛΗΓ</td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 9-0/¾¾</td><td>TO</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>• B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or hj</td><td>TO</td><td>B</td><td>TO</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>c / ο ^ γΑ</td><td>TO</td><td>TO</td><td> 8</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ú ^ o ^ A</td><td>B</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ ox ^ A Λ <Χ</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Ο ^ όγζΓ'Α</td><td> 8</td><td>B</td><td> 3</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Αο ^ 'Α</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>c ^ p ^ A</td><td> 3</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ÉAyOrA 0 ¿,<sub>CM</sub></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>WojpA <sup>0,</sup>CH<sub>to</sub></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>«/ OpA</td><td> 3</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CrXpCrA</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 5</td><td>Β</td><td>Β</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sub>ο</sub>.<sub>ο</sub> n</td><td>β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 3</td><td>Β</td><td>Β</td><td> 3</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>oo Xf ίΧΟγίΧ ^<sup>7</sup></td><td>Β</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>oo Χγ (ΧΟγΟ ^<sup>7</sup></td><td> 8</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup><χ</sup>^<sup>Λ</sup>ο<sub>ϊ</sub>σ '<^</td><td>Α</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Α</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><ν »~. πΑ.Όί O ^ XJ · ° ° ** J Η, Ο'Ο</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^^ OyCí »^</td><td>Α</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> °^<sup>Λ</sup>ο / χ »· ^</td><td>Α</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Α</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ίΧΟγΟξ'Φ</td><td>Β</td><td>Α</td><td>Β</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>LC </td><td>Β</td><td>Β</td><td>Α</td><td>β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>Β</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>c / o- ^ Aj</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>• Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cro ^ A</td><td>Β</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Cr ~ O ^<sup>to</sup>TO</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>e'Xro ¿rWíb 0</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>«, Χχο ^ 'Λ</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td>DC</td><td>DC</td><td>ΒΒ</td><td>DC</td><td></td><td></td><td></td><td></td>
<td>^ • ^ ΟγΟ'ΤΟ</td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or r * '·']) r '- * t **> io, p • N ^ S **</td><td>B</td><td> 0</td><td>B</td><td>and</td><td>AA</td><td>AA</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td><sup>ρ</sup>γ * Ίι Γ ^ ϊ τ * Ίι ° · «<sup>ύ</sup></td><td>B</td><td>B</td><td> 8</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cXGIO. ^</td><td>B</td><td> 6</td><td>TO</td><td>s</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CXOkXj ^ i,</td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>xx or \ x ^</td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>α ° τ<sup>οΛα</sup>^</td><td>B</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or Γ ^ ΪΓ ^ ΪΙ α ° ϊ ^ v »- 'n</td><td> 8</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>%. ° ατ x «~ y</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or r '^' rr'ii «v<sup>1 </sup>OT ^ ¿^<sup>%</sup>gp</td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or í ^ 7 τΊι crV ^ χχρ</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>στ<sup>σ</sup>Χ%> · '</td><td>B</td><td>TO</td><td>B</td><td> 6</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td> 8</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>1 ^ 7'τ '^ Ίΐ <sup>ü ο</sup></td><td>B</td><td>B</td><td> 3</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> *></td><td>B</td><td>B</td><td>B</td><td>, B</td><td>DC</td><td></td><td>DC</td><td></td><td></td><td></td><td></td><td></td>
<td>or</td><td>B.</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CUTyXx<sup>IU0</sup> V</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td> 8</td><td>B</td><td>B</td><td>BB</td><td>DC</td><td>BB</td><td>BB</td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td> 8</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B.</td><td> 8</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>φίο ^ Α</td><td>B</td><td> 8</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> 0^0^/¾</td><td> 8</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>-OrOyja ^ íb</td><td>TO</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><^ Όγ &&</td><td>TO</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ G ^ / Íi</td><td>B</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ϊλρ. Yes ** k ^ NxUl ^ J <í ° N ^ J</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> (¼°<sup>1</sup>¼¾ HC '' N *? ^</td><td> 8</td><td>B</td><td>, B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>* .ν <ΎΤ1 V , 3θΎ .Wy</td><td>B '</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>G // q, v MG- 'f'j'</td><td>TO</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ byCT ^</td><td>to</td><td></td><td>B.</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or ^^ í?</td><td>B</td><td>B</td><td>B</td><td>or</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>v</sup>xT<sup>or</sup>^ b2</td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td>Λ</td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8.</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> . <sup>ΰ</sup>-»·<sup>ς</sup>τ ATg5</td><td> 6</td><td>TO</td><td>B '</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>0. to <sub>Λ</sub> εΊι ° - ° ^ k'gp</td><td>B</td><td>B</td><td>S</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Α ^ Ο «VT: r</td><td>B</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>λ Ι ^ Ίΐ A-% ° c \ n XX</td><td> 6</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ τ ^ Ί ^ χρ</td><td> 8</td><td>TO</td><td> 3</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td> .3</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^°¾¾)</td><td>B</td><td>B</td><td> 3</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td> 3</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>• xyo ^</td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Α X OT<sup>N</sup> ιΓ1 ° ΐ °<sup>%</sup> J Ο Υ9<sup>w</sup> r ^ F ν · ^ Γ (| J</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Γ ^ ί * Ί *** ^ Ι or<sub>F</sub> or L, U! J · L · JL i; --- T; K'X</td><td>B.</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sub>F</sub> A | O. .0</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td> 8</td><td>BI</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>: b</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>χφ</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'</ r'V'S ^ l OO</td><td>B.</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>OR'<sup>tH</sup>> or ώγο<sup>-</sup>^^.</td><td>TO</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>Ι</sup>^ θ '<sup>ϊ</sup>^ Ν '' ^</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>QyO'kx ^^</td><td>B.</td><td>B</td><td>B</td><td>B.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>“ΥΊ r ^ íV ^ i °. <= X?</td><td>B</td><td>TO</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ΟγΟ ^ Ο '^ Β ^ Ρ</td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>R</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Q or</td><td>TO</td><td>TO</td><td> 8</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td> 8</td><td> 8</td><td>ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ixwkSL, &</td><td>TO</td><td> 8</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ςχο ^ α? ^ M II _J<sup>N</sup>| J ^</td><td>B</td><td>to</td><td> 8</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Wo ^</td><td> 8'</td><td> .8</td><td> 8</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>TO AAI</td><td> 8-</td><td>TO</td><td>B</td><td>δ</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ofo / yA</td><td> 8</td><td> 8</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td> 8</td><td> 8</td><td> .8</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>c¿o / ^ - b6</td><td> 8</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td> 8</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>OO uv Γϊ -Qp</td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>í 'í ~ j Ύ1 ®' · «</td><td>TO</td><td>TO</td><td>B</td><td> 5</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>¿WVá ^ Η XJ Cj</td><td>TO</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>A Ιι ^ ΤΐΓ O X> xJsuX ^ ·· ^ «JLJ or</td><td>B</td><td> 8</td><td> 8</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Α</td><td>Β</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>. ijj 'cr—</td><td>Β</td><td>Α</td><td>Β</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>yxóoJk</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>oíbkxTt ^<sup>H</sup> 1J and j</td><td>Β</td><td>Β</td><td>Β</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ϊ 'T<sup>5</sup>/ ^ 1 ι ^^ 'Τ'ΐ ^ ΊΓ °' · ° • ^ Í9</td><td>β</td><td>Β</td><td>Β</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ 0¾ Ότ</td><td>Α</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>r ti Γ 7 r ^ ιΓ <ι .α 7 <sup>Η</sup> X J-<sup>κ</sup></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>c¿b \ x ^ IjJ</td><td>Α</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ xJx<sup>5</sup>Ί ^ Ι Γ Λ<sup>1</sup> ΓΤ ο .. ° Μ-μΛ ^ ι</td><td>R</td><td>Β</td><td>Α</td><td>ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Α</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Ο λ ν-γΝ ^ 4 ^. «ysj V</td><td>Β</td><td>Β</td><td>Β</td><td> 5</td><td>ÁA</td><td>GC</td><td>ΑΑ</td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>α ί ^ Τ '<sup>></sup>Γ *<sup>!</sup>'Τ] Ό <3 αν-' and · »</td><td>Β</td><td>Β</td><td>Β</td><td>ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><1 Pj * Oa °</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td> 8</td><td>AND</td><td></td><td>DC</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ILrfJ</td><td>TO</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>«Νφί» T lJ</td><td>TO</td><td>B</td><td> 8</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><\ ίφ ^</td><td>TO</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'Ár<sup>0</sup>^?^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CU? ^ L ^</td><td>B</td><td>B</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cw ^</td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>opw</td><td>B</td><td>B</td><td>B</td><td>B-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ™’ <sup>B</sup> J</td><td>B,</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>τί r 7 ττ π <sup>or</sup>- .o xrn · “<Cr</td><td> 8</td><td> 8</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>And Cj</td><td>B</td><td> 8</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><ίι o, or w</td><td>B.</td><td>B</td><td>B</td><td>ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><XC<sup>neither</sup>Oi ° ^ and Cr</td><td>TO</td><td>TO</td><td> 8</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Ύ) r ^ 5 Ύί o. . « OR<sub>v</sub>TO<sub>n</sub>.s<sub>x</sub>^<sub>></sub>Saw?</td><td> 8</td><td>TO</td><td>TO</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>“ΤΊ <> Ύ1 o. : or vs?</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8.</td><td> 8</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or ^ Ύ'Ίι ΠΎΊ ο<sub>Λ</sub> θ</td><td>B</td><td>TO</td><td>TO.</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>FO fh Y'V'rYl «. - «</td><td>B</td><td>TO</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Oh<sup>or</sup>t ^ »<sup>;</sup>: xp</td><td> 8</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>F 6 fu <sup>or</sup>s<sup>or</sup>1 # IJ Cj</td><td>B</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td>to</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>TO</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>V 'l'T</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>O 'OyO<sup>TO</sup>OL<sub>and</sub>% ^ f- ^ p 'I **'!</td><td>TO</td><td>B</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or gH * γ ** Ίι r Y * - ° L · JL jü JL · JL 'g: · _ *. to Λ iQr</td><td> 8</td><td>.to</td><td>TO</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Γ * ^ * ϊι ι ^ ί'τΎθ, .o Δ KY Ί N '^ r nd</td><td>B</td><td>to</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>-Π <sub>N</sub>O 13% ¼ ° N ^ Y | 1 J</td><td> 8</td><td>TO</td><td>to</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ PsP '^</td><td> 8</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CX j3 kX%<sup>9 h</sup>¿?</td><td> 8</td><td> 8</td><td> 8</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>C ^ Yg;</td><td> 8</td><td>TO</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>9r ^ 5p</td><td>B</td><td>B</td><td>to</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td> 8</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B-</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B:</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td>BB</td><td>DC</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>Q</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>W ^ l ^</td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'ÍG ^' - g '</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ο<sup>F</sup>X1Xj ιίΧν ^ <sub>F</sub> jT 15 T * ex</td><td>TO</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>(** 5 Γ ^ γ ^ γΆΙ O. O</td><td>TO</td><td>TO</td><td>B<sup>:</sup></td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td> 8</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>^ oW</td><td>fi;</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>O ^ O ^ gp</td><td>B</td><td>TO</td><td>TO</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>-TO?</td><td>B</td><td>B</td><td> 8</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>XócAj ^</td><td>B</td><td>B</td><td> 8</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>r</sup>^ r Tjj</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td> ^0/¾</td><td>Β</td><td>Β</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>& 'ϊ ίττΊΐ ο. ο</td><td>Β</td><td> 8</td><td>Α</td><td>Β</td><td>ΑΑ</td><td>DC</td><td>ΑΑ</td><td>ΒΒ</td><td></td><td></td><td></td><td></td>
<td>H¿X.oVl ^</td><td>Β</td><td>Β</td><td>Β<sup>:</sup></td><td>Β</td><td>ΑΑ</td><td>ΑΑ</td><td>ΑΑ</td><td>ΑΑ</td><td></td><td>ΑΑ</td><td></td><td>ΑΑ</td>
<td>«Ο. Ο ξίν ^. 't?</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>π <sup>c</sup><sup>4</sup>C1 (Ί uv</td><td>Β</td><td>β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>cxo \ i: ^<sup>c</sup> 'ί ». “AJ</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td>ΑΑ</td><td>ΑΑ</td><td>ΑΑ</td><td>ΑΑ</td><td></td><td></td><td></td><td></td>
<td>α ^ ο \ ψ ^ ; r¿r</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>wW</td><td>Β</td><td>Β</td><td>Β</td><td>Ε</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td> 1</td><td></td><td></td><td></td>
<td>ch, and</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'tY c-rSn ^ o ^ XO T></td><td>TO</td><td>B</td><td>TO.</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>WYíp</td><td>B</td><td>B</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'Yii Yr1i o. or</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'Ύ /' Ίι ° v ° and ^</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>í ^ j Vi ° · - VH »N <S <</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>CRO ^ n T 'tJ</td><td>TO</td><td>TO</td><td>TO</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>□ X * Xi r 'Ϋ ^ ν ^' Ίι ° · °</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sub>F</sub>£ W<sup>x</sup>O ^ Y 8 AJ</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Γ * ^ r ^ 7 t ^ íi o. that</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or Γ *<sup>8</sup>^ ί ^ ι'Τ *** ')! °. ° r> S ΰ Y> <^ and N * ^ p</td><td>B</td><td>B</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>0- Ο</td><td>TO</td><td>Β</td><td>Β</td><td>Β</td><td></td><td>ΑΑ</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>Β</td><td>Β</td><td>Β</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>/ ΧΟ'Χΐχ ^ Ν '<sup>Λ</sup>^ χ</td><td>Β</td><td>Β</td><td>S</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>H, C CK, <sup>Η</sup> 1 J</td><td>Α</td><td>Α</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>F CH, A ^ ιιΤ * Ίι ° - · ° X?</td><td>Α</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Α Ί ^ Ίϊ ο ο</td><td>Β</td><td>Α</td><td>Α</td><td>and</td><td>DC</td><td>DC</td><td>DC</td><td></td><td></td><td></td><td></td><td></td>
<td>«V-OyO ^ O-í ^ j</td><td>Α</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ΧΧ.Ο ^^ 'χρ</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>F Ο X</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td>DC</td><td>DC</td><td>ΒΒ</td><td></td><td></td><td></td><td></td><td></td>
<td>> 9 Γη Γ ^? VH 0, ο<sub>β</sub>αα, ~ ^ <sup>Nj</sup>Yn</td><td>Β</td><td>Β</td><td>Β</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Α Ι '<sup>5</sup>* ']! ο .ο Ότ</td><td>Α</td><td>Β</td><td>Α</td><td>Α</td><td>DC</td><td>DC</td><td>DC</td><td></td><td></td><td></td><td></td><td></td>
<td>'CuoVi ^</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>οχ-Α ^</td><td>Β</td><td>Β</td><td>Α</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ο ηΆ ιΑ °. .ο Ν-Ά Μ</td><td>Β</td><td>Β</td><td>Β</td><td>Β</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>ΓΆ Γι '^ Ι ^ ΐΙ ©. -Ο GOES. .ν JU »Uk, s ^ -> · Χ ^<sub>Β</sub>- k '*' 'x</td><td>Β</td><td>Α</td><td>Α</td><td>Α</td><td>ΑΑ</td><td>ΑΑ</td><td>ΑΑ</td><td>ΑΑ</td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>r α 'XX> Ο jOl vl · ^</td><td>B</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Zk ^ O ^ XX ^ 'P h 11 J N- ^ f ^ irj</td><td>TO</td><td>TO</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>άχά ^ · ^</td><td>B</td><td>TO</td><td>B</td><td> 8</td><td>BB</td><td>DC</td><td>BB</td><td>BB</td><td>BB</td><td>BB</td><td>DC</td><td>BB</td>
<td>FO jlI Ój Xl<sup>1</sup>-.’..</td><td>B</td><td>TO</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>B</td><td>TO</td><td>B</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>X</td><td>TO</td><td>TO</td><td>B</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>xoXpp v</td><td>B</td><td>B</td><td>B</td><td>AND</td><td>BB</td><td>DC</td><td>BB</td><td></td><td></td><td></td><td></td><td></td>
<td>C ^ V ^ rP] 9. .O .IW ^ ÜyMvJ nPL ^ ÍI. ^ S <sup>n</sup> Xj</td><td>TO</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>or pp wj<sup>V</sup> N * p ^</td><td>B</td><td>TO</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td><sup>F</sup><wXpp</td><td>B</td><td>B</td><td>B</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>XkCÓO. ^</td><td>B</td><td>to</td><td>B</td><td>and</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>'' φυΟΧφ ^</td><td>B</td><td>B</td><td>B.</td><td> 8</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>f> o</td><td> 8</td><td>B</td><td> 8</td><td>AND</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>puO ^ XX ^ p, V</td><td> 8</td><td>B</td><td>B ''</td><td>B</td><td>BB</td><td>DC</td><td>BB</td><td>BB</td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>B</td><td> 3</td><td>and</td><td>AA</td><td>BB</td><td>AA</td><td>BB</td><td>AA</td><td>DC</td><td></td><td>AA</td>
<td></td><td> 8</td><td> 8</td><td> 8</td><td>AND</td><td></td><td>DC</td><td>BB</td><td> 83</td><td>BB</td><td>DC</td><td>DC</td><td>BB</td>
<td>ζ ^ θ \ Χ ^ H, C CH, Η IT J</td><td>TO</td><td>TO</td><td>B</td><td>B</td><td>AA</td><td>AA</td><td>AA</td><td>AA</td><td></td><td>AA</td><td></td><td>AA</td>
<td>Q ^ O ^ XX ^ * ^</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Ο ^ Ο ^ ΧΧ ^ ρ. R</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>Q ^ O ^ XX ^ pj v</td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>TO</td><td>TO</td><td>TO</td><td>TO</td><td>AA</td><td> 80</td><td>AA</td><td>AA</td><td></td><td></td><td></td><td></td>
<td>• / S ° A</td><td>TO</td><td>TO</td><td>B</td><td>B</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
The construction details and the arrangement of the components that are set forth in the following description or that are illustrated in the drawings are not intended to be taxative. The modalities can be implemented or carried out in several ways. Also, the wording and terminology used herein serve descriptive purposes and should not be construed as restrictive. The use of what it includes, that it comprises or that it has that it contains, that implies, and variations of the same in the present, is intended to cover the items listed below and the equivalents of these as well as the additional items.
Compounds
Compounds and compositions that activate wild-type PKR and / or various mutant PKRs such as those described herein are described herein.
In one embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided:
<img file="MX367387B_D0003.tif" />
where:
W, X, Y and Z are each independently selected from CH or N;
D and DI are independently selected from a link or NRb;
A is optionally substituted aryl or optionally substituted heteroaryl;
L is a bond, -C (O) -, - (CRcRc) m-, -0C (0) -, - (CRcRc) m
OC (O) -, - (CRcRc) mC (O) -, -NRbC (S) - or -NRbC (O) - (where the point of attachment to R1 is on the left side);
R1 is selected from alkyl, cycloalkyl, aryl, heteroariium and heterocyclyl; each of which is substituted with 0-5 occurrences of Rd;
each R3 is independently selected from halo, haloalkyl, alkyl, hydroxyl and ORa, or two adjacent R3, together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;
each Ra is independently selected from alkyl, acyl, hydroxyalkyl and haloalkyl;
each Rb is independently selected from hydrogen and alkyl;
each Re is independently selected from hydrogen, halo, alkyl, alkoxy and haloalkoxy, or two Re, together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl;
each Rd is independently selected from halo, haloalkyl, haloalkoxy, alkyl, alkynyl, nitro, cyano, hydroxyl, -C (O) Ra, -OC (O) Ra, -C (O) ORa, -SRa, -NRaRb and - ORa, or two Rd, together with the carbon atom to which they are attached form an optionally substituted heterocyclyl;
nesO, the 2;
m is 1, 2 or 3;
h is 0, 1, 2; and g is 0, 1 or 2.
In certain embodiments, a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided:
<img file="MX367387B_D0004.tif" />
(I where:
W, X, Y and Z are each independently selected from CH or N;
D and DI are independently selected from a link or NRb;
A is optionally substituted bicyclic heteroaryl;
L is a bond, -C (O) -, - (CRcRc) m-, -OC (O) -, - (CRcRc) mOC (O) -, - (CRcRc) mC (O) -, -NRbC (S ) - or -NRbC (O) -;
R1 is selected from alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; each of which is substituted with 0-5 occurrences of Rd;
each R3 is independently selected from halo, haloalkyl, alkyl, hydroxyl and -ORa, or two adjacent R3, together with the carbon atoms to which they are attached form an optionally substituted cyclyl; each Ra is independently selected from alkyl, acyl, hydroxyalkyl and haloalkyl;
each Rb is independently selected from hydrogen and alkyl;
each Re is independently selected from hydrogen, halo, alkyl, alkoxy and haloalkoxy, or two Re, together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl;
each Rd is independently selected from halo, haloalkyl, haloalkoxy, alkyl, alkynyl, nitro, cyano, hydroxyl, -C (O) Ra, -OC (O) Ra, -C (O) ORa, -SRa, -NRaRb and - ORa, or two Rd, together with the carbon atom to which they are attached form an optionally substituted heterocyclyl;
n is 0, 1 or 2;
m is 1, 2 or 3;
h is 0, 1, 2; and g is 0, 1 or 2. In some modalities, h is 1. In some modalities, h is 2.
In some modalities, g is 1. In some modalities, g is 2.
In some modalities, both h and g are 1. In some modalities, h is 1 and g is 2. In some modalities, g is 1 and h is 2.
<td>In some</td><td>modalities,</td><td>W</td><td>X /</td><td>Y and Z are</td><td>CH.</td><td>In</td><td>some</td>
<td>modalities, to</td><td>minus one of</td><td>W</td><td>X,</td><td>, Y and Z is</td><td>N.</td><td>In</td><td>some</td>
<td>modalities, to</td><td>minus two of</td><td>W</td><td>X,</td><td>Y and Z are</td><td>N.</td><td>In</td><td>some</td>
<td>modalities, to</td><td>minus three of</td><td>w,</td><td>X,</td><td>Y and Z are N</td><td></td><td></td><td></td>
<td>In some</td><td>modalities,</td><td>w,</td><td>X,</td><td>Y, Z and the</td><td colspan="3">carbons at</td>
which are attached form a pyridyl ring. In some embodiments, W, X, Y, Z and the carbon atoms to which they are attached form a pyrimidyl ring. In some embodiments, W, X, Y, Z and the carbon atoms to which they are attached form a pyridazinyl ring.
In some modalities, W, X and Y are CH and Z is N.
In some modalities, X, Y and Z are CH and W is N.
In some modalities, D is NRb and DI is a link. In some embodiments, D is a link and DI is NRb. In some modalities, both D and DI are NRb. In some embodiments, Rb is alkyl (for example, methyl or ethyl). In some embodiments, Rb is hydrogen (H).
In some embodiments, A is a 9-10 membered bicyclic heteroaryl (eg, quinazolinyl, quinoxalinyl, cinolinyl, isoquinolyl, indolyl, benzoxazolyl, pyrrolopyridyl, pyrrolopyrimidyl, benzimidazolyl, benzthiazolyl or benzoxazolyl). In some embodiments, A is a 9-10 membered bicyclic heteroaryl containing N. In some embodiments, A is optionally substituted quinazolinyl (for example, 8-quinazolinyl or 4-quinazolin.yl), optionally substituted quinoxalinyl (for example, 5-quinoxalinyl), optionally substituted quinolinyl (for example, 4-quinolinyl or 8-quinolinyl ), optionally substituted cinolinyl (for example, 8-cinolinyl), optionally substituted isoquinolinyl, optionally substituted indolyl (7-indolyl), optionally substituted benzoxazolyl (for example, 7-benzoxazolyl), optionally substituted pyrrolopyridyl (for example, 4-pyrrolopyridyl), optionally substituted pyrrolopyrimidyl (for example, 4-pyrrolopyrimidyl), optionally substituted benzimidazolyl (for example, 7-benzimidazolyl), optionally substituted benzthiazolyl (for example, 4-benzthiazolyl, -4-benzthiazolyl or 7-benzthiazolyl) or optionally substituted benzoxazolyl (eg, 4-benzoxazolyl). In some embodiments, A is optionally substituted with halo. In some modalities, A is <sub>N</sub>^ J>
In some modalities, A is Cb. In some, c \ NN modalities, A is optionally substituted. In<sup>N</sup>\°/<sup>N </sup>some modalities, A is.
In some modalities, L is a link.
In some modalities, L is - (CRcRc) m- and m is 1. In some aspects of these modalities, each Re is hydrogen. In some aspects of these embodiments, one Re is alkyl (for example, methyl or ethyl) and the other Re is hydrogen. In some aspects of these modalities, a Re is halo (for example, fluorine) and a Re is hydrogen. In some aspects of these modalities, both Re are halo (for example, fluorine). In some aspects of these embodiments, a Re is alkoxy (for example, methoxy or ethoxy) and a Re is hydrogen. In some aspects of these modalities, both Re are alkoxy (for example, methoxy or ethoxy). In some aspects of these modalities, two Re, together with the carbon to which they are attached, form a cycloalkyl (for example, cyclopropyl).
In some modalities, L is - (CRcRc) m- and m is 2. In some aspects of these modalities, each Re is hydrogen. In some aspects of these embodiments, 1 Re is alkyl (for example, methyl or ethyl) and each of the other Re is hydrogen. In some aspects of these modalities, two Re, together with the carbon to which they are attached form a cycloalkyl (for example, cyclopropyl) and each of the other two Re is hydrogen.
In some modalities, L is - (CRcRc) m- and m is 3. In some aspects of these modalities, each Re is hydrogen.
<td>In some modalities, L is —C (0) -.</td>
<td>In some modalities, L is -0-C (0) -.</td>
<td>In some modalities, L is NRbC (O) - and Rb is H. In</td>
some modalities, L is NRbC (S) - and Rb is H.
In some modalities, L is - (CRcRc) mC (O) - and m is 1. In some aspects of these modalities, each Re is hydrogen.
In some aspects of these embodiments, a Re is alkyl (for example, methyl or ethyl) and a Re is hydrogen. In some aspects of these embodiments, both Re are alkyl (for example, methyl or ethyl).
In some modalities, L is - (CRcRc) mC (O) - and m is 2. In some aspects of these modalities, each Re is hydrogen.
In some modalities, L is - (CRcRc) mC (O) - and m is 3. In some aspects of these modalities, each Re is hydrogen.
In some embodiments, R1 is alkyl substituted with 0-5 occurrences of Rd (eg, methyl, ethyl, n-propyl, i-propyl or n-butyl). In some embodiments, R1 is methyl, ethyl, n-propyl, i-propyl or n-butyl. In some embodiments, R1 is ethyl or propyl (n-propyl or i-propyl). In some aspects of these modalities, L is a link,
-CH2-, -C (O) -, or -O (CO) -. In some aspects of these modalities, L is -0 (C0) -.
In some embodiments, R1 is alkyl substituted with 1 appearance of Rd (for example, methyl, ethyl, n-propyl, i-propyl or n-butyl). In some embodiments, R1 is methyl, ethyl or n-propyl substituted with 1 occurrence of Rd. In some aspects of these modalities, Rd is halo (for example, fluorine or chlorine). In some aspects of these modalities, Rd is -C (O) ORa. In some aspects of these embodiments, Ra is alkyl (for example, methyl or ethyl). In some aspects of these modalities, L is -NHC (O) -.
In some embodiments, R 1 is alkyl substituted with 2 occurrences of Rd (for example, methyl, ethyl, n-propyl, i-propyl or n-butyl). In some embodiments, R1 is methyl, ethyl or n-propyl substituted with 2 occurrences of Rd. In some embodiments, R1 is n-propyl substituted with 2 occurrences of Rd. In some aspects of these modalities, 1 Rd is cyano and the other Rd is -NRaRb. In some aspects of these modalities, Ra and Rb are hydrogen. In some aspects of these modalities, L is -CH2-.
In some embodiments, R1 is heteroaryl substituted with 0-5 occurrences of Rd (eg, monocyclic heteroaryl containing S, monocyclic heteroaryl containing N or bicyclic heteroaryl containing N). In some embodiments, R 1 is a 5-8 membered monocyclic heteroaryl substituted by 0-5 occurrences of Rd (eg, thiophenyl, pyridyl, pyrimidyl or pyrazyl). In some embodiments, R1 is pyridyl substituted with 0-5 occurrences of Rd (eg, 2-pyridyl, 3-pyridyl or 4-pyridyl), pyrimidyl substituted with 0-5 occurrences of Rd (eg, 2-pyrimidium or 5 -pyrimidyl) or pyrazinyl substituted with 0-5 occurrences of Rd (for example, 2-pyrazinyl). In some embodiments, R1 is thiazolyl substituted with 0-5 occurrences of Rd (eg, 2-thiazolyl or 5-thiazolyl). In some embodiments, R1 is pyrimidyl substituted with 0-5 occurrences of Rd (eg, 2-pyrimidyl). In some embodiments, R1 is thiadiazolyl substituted with 0-5 occurrences of Rd (eg, 4-thiadiazoiyl). In some embodiments, R1 is pyrrolyl substituted with 0-5 occurrences of Rd (eg, 2-pyrrolyl). In some aspects of these modalities, L is a link, -CH2-, -C (O) - or -O (CO) -. In some embodiments, R1 is pyridyl (for example, 2-pyridyl, 3-pyridyl or
4-pyridyl).
In some embodiments, R1 is pyridyl (for example, 2-pyridyl, 3-pyridyl or 4-pyridyl) substituted by 1 occurrence of Rd. In some aspects of these embodiments, Rd is -OC (O) Ra. In some aspects of these modalities, Rd is -ORa. In some aspects of these modalities, Rd is
-C (O) ORa. In some aspects of these embodiments, Rd is alkyl (for example, methyl or ethyl). In some aspects of these embodiments, Rd is haloalkyl (for example, trifluoromethyl). In some aspects of these modalities, Rd is halo (for example, fluorine or chlorine). In some aspects of these embodiments, Ra is alkyl (for example, methyl or ethyl). In some aspects of these modalities, L is -CH2-. In some embodiments, R1 is pyridyl (for example, 2-pyridyl, 3-pyridyl or 4-pyridyl) substituted with 2 occurrences of Rd. In some aspects of these modalities, one Rd is -C (O) ORa and the other Rd It's -ORa. In some aspects of these embodiments, Ra is alkyl (for example, methyl or ethyl). In some aspects of these modalities, both Rd are halo (for example, fluorine or chlorine). In some aspects of these modalities, L is -CH2-.
In some embodiments, R1 is pyrimidyl (for example, 2-pyrimidyl or 5-pyrimidyl). In some aspects of these modalities. L is a link.
In some embodiments, R1 is pyrimidyl (for example, 2-pyrimidyl or 5-pyrimidyl) substituted with 1 appearance of Rd. In some aspects of these embodiments, Rd is halo (e.g., fluorine or chlorine).
In some embodiments, R1 is pyrazinyl (for example, 2-pyrazinyl). In some aspects of these modalities. L is a link.
In some embodiments, R1 is thiazolyl (for example, 2-thiazolyl, 4-thiazolyl or 5-thiazolyl). In some aspects of these modalities, L is —C (0) -.
In some embodiments, R1 is thiazolyl (for example, 2-thiazolyl, 4-thiazolyl or 5-thiazolyl) substituted with 1 occurrence of Rd. In some aspects of these modalities, Rd is alkyl (for example, methyl or ethyl). In some aspects of these modalities, L is -C (O) -.
In some embodiments, R1 is thiophenyl substituted with 0-5 occurrences of Rd (eg, 2-thiophenyl). In some embodiments R1 is thiophenyl.
In some embodiments, R1 is thiadiazolyl (for example, 4-thiadiazolyl).
In some embodiments, R1 is pyrrolyl (for example, 2-pyrrolyl).
In some embodiments, R1 is cycloalkyl substituted with 0-5 occurrences of Rd (eg, cyclopropyl, cyclopentyl or cyclohexyl). In some embodiments R1 is cyclopropyl. In some embodiments R1 is cyclohexyl. In some embodiments R1 is cyclopentyl. In some aspects of these modalities, L is -CH2-C (O) -. In some modalities. R1 is aryl substituted with 0-5 occurrences of Rd. In some aspects of these modalities, L is a link,
-CH2-, -C (O) - or -O (CO) -.
In some embodiments, R1 is aryl (for example, phenyl). In some embodiments, R1 is phenyl. In some aspects of these modalities, L is a link, -CH2-, -C (O) or -O (CO) -.
In some modalities, R1 is phenyl substituted with 1 appearance of Rd. In some aspects of these modalities, Rd is ortho substituted. In some aspects of these modalities, Rd is a substituted goal. In some aspects of these modalities, Rd is for substituted. In some aspects of these modalities, Rd is halo (for example, fluorine, bromine or chlorine). In some aspects of these embodiments, Rd is alkyl (for example, methyl, ethyl, isopropyl, t-butyl, n-butyl or n-pentyl). In some aspects of these embodiments, Rd is haloalkyl (for example, trifluoromethyl). In some aspects of these modalities, Rd is -ORa. In some aspects of these modalities, Rd is -C (O) Ra. In some aspects of these modalities, Rd is SRa. In some aspects of these modalities, Rd is C (O) ORa. In some aspects of these modalities, Rd is cyano. In some aspects of these modalities, Rd is NRaRb. In some aspects of these embodiments, Rd is haloalkoxy (for example, difluoromethoxy or trifluoromethoxy). In some aspects of these modalities, Rd is hydroxyl. In some aspects of these modalities, Rd is -OC (O) Ra. In some aspects of these embodiments, Rd is alkynyl (for example, 1-hexinyl). In some aspects of these embodiments, Rd is haloalkyl (for example, trifluoromethyl). In some aspects of these embodiments, Ra is alkyl (for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl or n-pentyl). In some aspects of these embodiments, Ra is hydroxyalkyl (for example, 2-hydroxylethyl). In some aspects of these embodiments, Ra and Rb are alkyl (for example, methyl or ethyl). In some aspects of these embodiments, Ra is acyl (for example, acetyl) and Rb is hydrogen. In some aspects of these modalities, L is a link, -CH2-, -C (O) - or -O (CO).
In some modalities, R1 is phenyl substituted with 2 occurrences of Rd. In some aspects of these modalities, both Rd are halo (for example, fluorine or chlorine). In some aspects of these embodiments, both Rd are alkyl (for example, methyl or ethyl). In some aspects of these embodiments, 1 Rd is alkyl (for example, methyl or ethyl) and the other is -ORa. In some aspects of these modalities, 1 Rd is halo (for example, fluorine or chlorine) and the other Rd is -ORa. In some aspects of these modalities, both Rd are -ORa. In some aspects of these modalities, 1 Rd is halo (for example, fluorine or chlorine) and the other Rd is hydroxyl. In some aspects of these modalities, 1 Rd is halo (for example, fluorine or chlorine) and the other is haloalkyl (for example, trifluoromethyl). In some aspects of these modalities, 1 Rd is -ORa and the other Rd is -C (O) ORa. In some aspects of these modalities, 1 Rd is -ORa and the other Rd is hydroxyl. In some aspects of these embodiments, 1 Rd is alkyl (for example, methyl or ethyl) and the other Rd is hydroxyl. In some aspects of these modalities, both Rd are hydroxyl. In some aspects of these embodiments, 1 Rd is halo (for example, fluorine) and the other Rd is haloalkyl (for example, trifluoromethyl). In some aspects of these modalities, both Rd are hydroxyl. In some aspects of these embodiments, one Rd is haloalkyl (for example, trifluoromethyl) and the other Rd is alkyl (for example, methyl). In some aspects of these embodiments, two Rd, together with the carbon atoms to which they are attached, form an optionally substituted heterocyclyl. In some aspects of these embodiments, two Rd, together with the carbon atoms to which they are attached, form an optionally substituted 5-7 membered heterocyclyl. In some aspects of these modalities, two Rd, together with the phenyl ring to which they are attached, form the following structure:
In some aspects of these embodiments, Ra is alkyl (for example, methyl or ethyl). In some aspects of these modalities, L is a link, -CH2-, -C (0) - or -O (CO) -.
In some modalities, R1 is phenyl substituted with 3 occurrences of Rd. In some aspects of these modalities, 3 Rd are halo (for example, fluorine or chlorine). In some aspects of these modalities, 2 Rd is halo (for example, fluorine or chlorine) and 1 Rd is hydroxyl. In some aspects of these embodiments, 1 Rd is halo (for example, fluorine or chlorine), 1 Rd is alkyl (for example, methyl) and 1 Rd is hydroxyl. In some aspects of these embodiments, 3 Rd are alkyl (for example, methyl or ethyl). In some aspects of these embodiments, 2 Rd are alkyl (for example, methyl or ethyl) and
Rd is hydroxyl. In some aspects of these modalities,
Rd are halo (for example, fluorine or chlorine) and 1 Rd is -ORa. In some aspects of these embodiments, Ra is alkyl (for example, methyl or ethyl). In some aspects of these modalities, 1 Rd is hydroxyl and 2 Rd is -ORa. In some aspects of these embodiments, Ra is alkyl (for example, methyl or ethyl). In some aspects of these modalities, 3 Rd are -ORa. In some aspects of these modalities, 3 Rd are halo (for example, fluorine or chlorine). In some aspects of these embodiments, Ra is alkyl (for example, methyl or ethyl). In some aspects of these modalities, L is a link, -CH2-, -C (O) - or -0 (C0) -.
In some embodiments, R1 is phenyl substituted with 4 occurrences of Rd. In some aspects of these modalities, 1 Rd is hydroxyl, 1 Rd is alkyl (for example, methyl or ethyl) and 2 Rd is -OR. In some aspects of these embodiments, Ra is alkyl (for example, methyl or ethyl). In some aspects of these modalities, L is a link, -CH2-, -C (O) - or -O (CO) -.
In some embodiments, R1 is heterocyclyl substituted with 0-5 occurrences of Rd.
In some embodiments, R1 is tetrahydrofuranyl substituted with 0-5 occurrences of Rd (eg, 2-tetrahydrofuranyl or 3-tetrahydrofuranyl). In some aspects of these embodiments, R1 is tetrahydrofuranyl (for example, 2-tetrahydrofuranyl or 3-tetrahydrofuranyl). In some aspects of these modalities, L is -C (O) -.
In some embodiments, R1 is azetidinyl substituted with 0-5 occurrences of Rd (eg, 3-azetidinyl). In some embodiments, R1 is azetidinyl (for example, 3azetidinyl). In some embodiments, R 1 is azetidinyl (for example, 3-azetidinyl) substituted with 1 occurrence of Rd. In some aspects of these embodiments, Rd is alkyl (for example, methyl or ethyl). In some aspects of these modalities. L is -C (O) -.
In some embodiments, R1 is 10-14 member bicyclic aryl substituted with 0-5 occurrences of Rd. In some embodiments, Rd is naphthyl substituted with 0-5 occurrences of Rd. In some modalities, Rd is naphthyl.
In some embodiments, L is a bond, - (CRcRc) m-, NRbC (O) -, - (CRcRc) mC (O) -, -C (O) - or -O (CO) -.
In some embodiments, L is a bond and R1 is alkyl, aryl or heteroaryl substituted with 0-5 occurrences of Rd. In some aspects of these embodiments, alkyl, aryl or heteroaryl of R1 is as described in any of the modalities and aspects previous.
In some embodiments, L is - (CRcRc) m- and R1 is cycloalkyl, aryl, heteroaryl or heterocyclyl substituted with 0-5 occurrences of Rd. In some aspects of these modalities, cycloalkyl, aryl, heteroaryl or heterocyclyl of R1 is as follows. It describes in any of the above modalities and aspects.
In some embodiments, L is -NRbC (O) - and Rb is hydrogen; and R1 is aryl substituted with 0-5 occurrences of Rd. In some aspects of these modalities, aryl of R1 is as described in any of the above modalities and aspects.
In some embodiments, L is - (CRcRc) mC (O) - and R1 is cycloalkyl, aryl or heteroaryl substituted with 0-5 occurrences of Rd. In some aspects of these modalities, cycloalkyl, aryl or heteroaryl of R1 is as described in any of the previous modalities and aspects.
In some embodiments, L is -C (O) - and R 1 is aryl, alkyl, or heteroaryl substituted with 0-5 occurrences of Rd. In some aspects of these embodiments, aryl, alkyl, or heteroaryl of R 1 is as described in Any of the above modalities and aspects.
In some embodiments, L is -OC (O) - and R1 is alkyl, aryl, or heterocyclyl substituted with 0-5 occurrences of Rd. In some aspects of these embodiments, alkyl, aryl, or heterocyclyl of R1 is as described in Any of the above modalities and aspects.
In some embodiments, L is - (CRcRc) m-OC (O) - and R1 is heterocyclyl or cycloalkyl substituted with 0-5 occurrences of Rd. In some aspects of these modalities, heterocyclyl or cycloalkyl of R1 is as described in any of the previous modalities and aspects.
In some modalities, n is 0. In some modalities, n is 1.
In some embodiments, R3 is alkyl for example, methyl or ethyl). In some modalities R3 is -ORa. In some aspects of these embodiments, Ra is alkyl (for example, methyl or ethyl). In some embodiments, R3 is halo (for example, fluorine or chlorine). In some embodiments R3 is hydroxyl. In some embodiments, R3 is haloalkyl (eg, trifluoromethyl).
In some modalities, n is 2.
In some embodiments, two adjacent R3, taken together with the carbon atoms to which they are attached form a heterocyclyl ring. In some modalities, both R3 are -ORa. In some embodiments, two adjacent R3, taken together with the carbon atoms to which they are attached form.
In certain embodiments, a compound is of formula (II) or a pharmaceutically acceptable salt thereof:
<img file="MX367387B_D0005.tif" />
(II) where L, Rl, R3, Ra, Rb, Re, Rd, Y, Z, m, hyg are as defined above in formula (I) or any of the modalities or aspects described herein.
In certain embodiments, A is aryl (e.g., phenyl or naphthyl) optionally substituted with 1 or 2 occurrences of R2, where each R2 is independently selected from halo, haloalkyl, aryl, heteroaryl,
<td>alkyl, -ORa,</td><td>-COORc,</td><td>or -CONRcRc;</td><td>Y</td><td>D,</td><td>DI, L, Rl,</td><td>R3, Ra,</td>
<td>Rb, Re, Rd, X,</td><td>AND Z,</td><td>W, n, m, h</td><td>Y</td><td>g</td><td>they are how I know</td><td>define</td>
<td>previously</td><td>in the</td><td>formula (I)</td><td></td><td> 0</td><td>anyone</td><td>of the</td>
modalities or aspects described herein. In some aspects of these modalities, D and DI are N. In some aspects of these modalities, at least one of W, X, Y and Z is N. In some aspects of these modalities, one of W, Y and Z is N ; h is 1 and g is 1.
In certain embodiments, A is heteroaryl (eg, monocyclic heteroaryl containing N or bicyclic heteroaryl containing N); and D, DI, L, Rl, R3, Ra, Rb, Re, Rd, X, Y, Z, W, n, m, hyg are as defined above in formula (I) or any of the modalities or aspects which are described herein. In some embodiments, A is 5-8 membered monocyclic heteroaryl (eg, pyridyl, pyrimidyl, or pyrazyl) and D, Di, L, Rl, R3, Ra, Rb, Re, Rd, X, Y, Z, W , n, m, hyg are as defined above in formula (I) or any of the modalities or aspects described herein. In some embodiments, A is a 5-8 membered monocyclic heteroaryl; and D, Di, L, Rl, R3, Ra, Rb, Re, Rd, X, Y, Z, W, n, m, hyg are as defined above in formula (I) or any of the modalities or aspects which are described herein. In some embodiments, A is optionally substituted pyridyl (for example
2-pyridyl, 3-pyridyl or
Optionally substituted 4-pyridyl) pyrimidyl (for example, 2-pyrimidyl or 5-pyrimidyl) or optionally substituted pyrazyl (for example, 2-pyrazyl); and L, Rl
R3, Ra, Rb
Re, Rd, Y
Z, m, hyg are as defined above in formula (I) or any of the modalities or aspects that the
<td>It was described:</td><td>Ben in the present.</td><td></td>
<td>In</td><td>some modalities,</td><td>A is substituted with 1</td>
<td>appearance</td><td>of R2; and D, DI, L, Rl,</td><td>R3, Ra, Rb, Re, Rd, X, Y, Z,</td>
<td>W, n, m,</td><td>hyg are how I know</td><td>defined above in the</td>
<td>formula (</td><td>I) or any of the</td><td>modalities or aspects that</td>
<td>describe</td><td>at the moment. In</td><td>some aspects of these</td>
<td colspan="2">modalities, R2 is alkyl (for</td><td>example, methyl or ethyl). In</td>
<td>some to</td><td colspan="2">Species of these modalities, R2 is halo. In some</td>
<td>aspects</td><td>of these modalities,</td><td>R2 is fluorine (F). In some</td>
<td>aspects</td><td>of these modalities,</td><td>R2 is bromine (Br). In some</td>
<td>aspects</td><td>of these modalities,</td><td>R2 is chlorine (Cl) · In some</td>
<td>aspects</td><td>of these modalities</td><td>, R2 is -ORa. In some</td>
<td>aspects methyl).</td><td>of these modalities,</td><td>Ra is alkyl (for example,</td>
<td>In</td><td>some modalities,</td><td>A is substituted with 2</td>
appearances of R2; and D, DI, L, Rl, R3, Ra, Rb, Re, Rd, X, Y,
Z, W, η, m, hyg are as defined above in formula (I) or any of the modalities or aspects described herein. In some aspects of these modalities, both R2 are halo (for example, fluorine or fluorine and chlorine). In some aspects of these embodiments, both R2 are alkyl (for example, methyl). In some aspects of these modalities, both R2 are -ORa. In some aspects of these modalities, one R2 is halo and the other is -ORa. In some aspects of these modalities, one R2 is bromine (BR) and the other is -ORa. In some aspects of these modalities, one R2 is chlorine (Cl) and the other is -ORa. In some aspects of these modalities, one R2 is fluorine (F) and the other is -ORa. In some aspects of these embodiments, Ra is alkyl (for example, methyl or ethyl). In some aspects of these modalities, both R2 are -ORa. In some aspects of these modalities, two -ORa, taken together with the carbon atoms to which they are attached, form a heterocyclyl. In some modalities, A is and D, Di, L, Rl, R3, Ra, Rb,
Re, Rd, X, Y, Z, W, n, m, hyg are as defined above in formula (I) or any of the modalities or aspects described herein.
In another embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided:
<img file="MX367387B_D0006.tif" />
(I where:
W, X, Y and Z are each independently selected from CH or N;
D and DI are independently selected from a link or NRb;
A is optionally substituted aryl or optionally substituted heteroaryl;
L is a bond, -C (0) -, - (CRcRc) m-, -0C (0) - or -C (O) NRb-;
R1 is independently selected from alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; each of which is substituted with 0-3 occurrences of Rd;
each R3 is independently selected from halo, haloalkyl, alkyl, alkyl, hydroxyl and ORa, or two adjacent R3, taken together with the carbon atoms to which they are attached form an optionally substituted cyclyl;
each Ra is independently selected from alkyl and haloalkyl;
each Rb is independently selected from hydrogen and alkyl;
each Re is independently selected from hydrogen, halo, alkyl, alkoxy and halo alkoxy or two Re, taken together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl;
each Rd is independently selected from halo, haloalkyl, alkyl, nitro, cyano and -ORa, or two Rd taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;
n is 0, 1 or 2;
m is 1, 2 or 3;
h is 0, 1, 2; and g is 0, 2; In some aspects of this modality, A, D, DI, L, Rl, R3, Ra, Rb, Re, Rd, X, Y, Z, W, n, m, hyg are as defined above in any of the modalities or aspects described herein.
In another embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided:
<img file="MX367387B_D0007.tif" />
OR (I) where:
W, X, Y and Z are each independently selected from CH or N;
D and DI are independently selected from a link or NRc;
A is optionally substituted aryl or optionally substituted heteroaryl;
R1 is independently selected from alkyl, optionally substituted aryl and optionally substituted heteroaryl;
each R3 is independently selected from halo, haloalkyl, alkyl and ORa;
each Ra is independently selected from optionally substituted alkyl, haloalkyl and heteroaryl;
each Rb is independently alkyl;
each Re is independently selected from hydrogen or alkyl;
nes 0, 1 or 2;
h is 0, 1, 2; and g is 0, 2; In some aspects of this modality, A, D, DI, L, Rl, R3, Ra, Rb, Re, Rd, X, Y, Z, W, n, m, hyg are as defined above in any of the modalities or aspects described herein.
In another embodiment, a pharmaceutically acceptable compound or salt of the formula (Ib) or a pharmaceutical composition comprising a pharmaceutically acceptable compound or salt of the formula (Ib) is provided:
<img file="MX367387B_D0008.tif" />
(Ib);
where A, L, Rl, R3, Ra, Rb, Re, Rd, W, X, Z, m, hyg are as defined above in formula (I) or any of the modalities or aspects described herein. .
In some modalities, X, W and Z are CH. In some modalities, one of X, W and Z is N and the other two of X, W and Z are CH.
In another embodiment, a pharmaceutical composition comprising a pharmaceutically acceptable compound or salt of the formula (Ic) or a pharmaceutical composition comprising a pharmaceutically acceptable compound or salt of the formula (Ic) is provided:
<img file="MX367387B_D0009.tif" />
(Ic);
where A, L, Rl, R3, Ra, Rb, Re, Rd, W, X, Y, m, hyg are as defined above in formula (I) or any of the modalities or aspects described herein. .
In some modalities, X, Y and W are CH. In some modalities, one of X, Y and W is N and the other two of X, Y and W are CH.
In another embodiment, a pharmaceutically acceptable compound or salt of the formula (Id) or a pharmaceutical composition comprising a pharmaceutically acceptable compound or salt of the formula (Id) is provided:
(Id);
where A, L, Rl, R3, Ra, Rb, Re, Rd, Y, Z, m, hyg are as defined above in formula (I) or any of the modalities or aspects described herein.
In some modalities, Y and Z are CH. In some embodiments, one of Y and Z is N and one of Y and Z is CH.
In another embodiment, a pharmaceutically acceptable compound or salt of the formula (le) or a
100 '' S 'pharmaceutical composition comprising a pharmaceutically acceptable compound or salt of the formula (le):
<img file="MX367387B_D0010.tif" />
where A, L, Rl, R3, Ra, Rb, Re, Rd, W, X, Y, Z, m, hyg are as defined above in formula (I) or any of the modalities or aspects described in the present.
In certain embodiments, the compounds of the examples of Formula I include the compounds described in Table 1 and in the Examples.
The compounds described herein are useful as activators of PKR mutants that have a lower activity compared to those of the wild type, and are therefore useful for the methods of the present invention. Such mutations in PKR can affect enzyme activity (catalytic efficiency), regulatory properties (modulation by fructose bisphosphate (FBP) / ATP), and / or the thermostability of the enzyme. Examples of such mutations are described in Valentini et al, JBC 2002. Some examples of mutants that are activated by the compounds described herein include G332S, G364D, T384M, G37E,
101
R479H, R479K, R486W, R532W, R510Q and R490W. Without being limited by theory, the compounds described herein affect the activities of PKR mutants by activating PKR mutants that do not respond to FBP, restoring thermostability to mutants with decreased stability, or restoring catalytic efficiency to defective mutants. The activation activity of the present compounds against PKR mutants can be evaluated following a method described in Example 1. The compounds described herein are also useful as wild type PKR activators.
In one embodiment, to increase the life of the red blood cells, a pharmaceutical compound, composition or composition described herein is added directly to whole blood cells or extracorporeal red blood cell concentrates or provided to the patient directly (e.g., by ip administration , iv, im, oral, inhalation (aerosol administration), transdermal, sublingual and other routes of administration). Without being limited by theory, the compounds described herein increase the life of RBCs, thus counteracting the aging of stored blood, affecting the rate of 2,3-DPG release from the blood. A decrease in the level of 2,3-DPG concentration includes a shift to the left of the hemoglobin dissociation curve and
102 oxygen and changes the allosteric equilibrium to R, or oxygen state, thus producing a therapeutic inhibition of intracellular polymerization underlying sickle cell disease increasing oxygen affinity due to depletion of 2,3-DPG, thus stabilizing the more soluble oxyhemoglobin. Accordingly, in one embodiment, the compounds and pharmaceutical compositions described herein are useful as antidrepanocytosis agents. In another embodiment, to regulate 2,3-diphosphoglycerate, a pharmaceutical compound, composition or composition described herein is added directly to whole blood cells or extracorporeal erythrocyte concentrates or provided to the patient directly (e.g., by ip administration, iv, im, oral, inhalation (aerosol administration), transdermal, sublingual and other routes of administration).
A compound described herein may be an activator of a PKR, for example a wild-type (wt) or mutated PKR (for example, R510Q, R532W or T384W). Examples of compounds are shown in Table 1. As shown in Table 1, A refers to a compound that has a% activation at 1 µΜ from 1 to 100. B refers to a compound that has a% of activation at 1 μΜ from 101 to 500. C refers to a compound that has a% activation at 1 μΜ of> 500.
103
In Table 1, a compound described herein may also have an AC50 of wild type PKR, PKR R532W, PKR T384W, PKR G332S, PKR G364D, PKR G37E and / or PKR R479H. AA refers to an AC50 less than 100 nM, BB refers to an AC50 from 101 nM to 500 nM and CC refers to an AC50 greater than 500 nM.
Other examples of compounds can be found in International Patent Application No. PCT / US2010 / 040486 (for example, in Figure 1) published as WO 2011/002817 which is incorporated herein in its entirety by this reference.
The compounds described herein can be performed using a variety of synthetic techniques.
Scheme 1.
<img file="MX367387B_D0011.tif" />
<img file="MX367387B_D0012.tif" />
<img file="MX367387B_D0013.tif" />
<img file="MX367387B_D0014.tif" />
R, Br csjco ,. dioxane
<img file="MX367387B_D0015.tif" />
HATU, NMM
DMF.ta, 12h
<img file="MX367387B_D0016.tif" />
Rl R<sup>2</sup>, R<sup>J</sup>.y π = COfTlO It is defined herein
Scheme 1 above is an example of a scheme that
104 illustrates a representative synthesis of certain compounds described herein. Sulfonyl Chloride 1 is reacted with amine 2 under standard coupling conditions to produce ester 3. Hydrolysis of 3 using lithium hydroxide generates carboxylic acid 4. Piperazine (5) with the appropriate bromide under standard palladium coupling conditions to provide 7. The carboxylic acid 4 is then treated with a piperazine derivative 7 to produce the final compound 8.
The compounds described herein can be performed using procedures described in International Patent Application No. PCT / US2010 / 040486 published as WO 2011/002817 which is incorporated herein in its entirety by this reference.
As the expert can recognize, the methods for synthesizing the compounds of the formulas herein will be apparent to those skilled in the art. Additionally, the various synthetic steps can be performed in an alternative sequence or order to provide the desired compounds. Synthetic chemistry transformations and protective group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those described in R. Larock,
105
Comprehensive Organic Transformations, VCH Publishers (1989); TW Greene and PGM Wuts, Protective Groups in Organic Synthesis, 2<sup>to</sup> Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994) and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and later editions of these.
The compounds provided herein may contain one or more asymmetric centers and therefore may occur as racemates and racemic mixtures, simple enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included within the scope. Unless otherwise indicated when a compound is named or represented by a structure without specifying the stereochemistry and has one or more chiral centers, it should be understood that it represents all possible stereoisomers of the compound. The compounds provided herein may also contain bonds (for example, carbon-carbon bonds) or substituents that may restrict the rotation of bonds, for example, the restriction that results from the presence of a double ring or bond. Accordingly, all cis / trans and E / Z isomers are expressly included.
106
The compounds provided herein (for example, of Formula I) may also comprise one or more isotopic substitutions. For example, H may be in any isotopic form, including 1H, 2H (D or deuterium) and 3H (T or tritium); C can be in any isotopic form, including 12C, 13C and 14C; 0 can be in any isotopic form, including 160 and 180; and the like The compounds provided herein may also be represented in multiple tautomeric forms, in such cases, it expressly includes all tautomeric forms of the compounds described herein, even though only an individual tautomeric form could be represented (eg, alkylation of a ring system can result in alkylation at multiple sites, all of these reaction products are expressly included). All these isomeric forms of said compounds are expressly included. All crystal forms of the compounds described herein are expressly included.
The compounds provided herein include the compounds themselves, as well as their salts and their prodrugs, if applicable. A salt, for example, can be formed between an anion and a positively charged substituent (eg, amino) in a compound described in the
107 Present. Suitable anions include chloride, bromide, iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate and acetate. Similarly, a salt can also be formed between a cation and a negative charge substituent (eg, carboxylate) in a compound described herein. Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion and an ammonium cation such as tetramethylammonium ion. Examples of prodrugs include esters and other pharmaceutically acceptable derivatives which, upon administration to a subject, are capable of providing active compounds.
The compounds provided herein can be modified by adding appropriate functionalities to improve the selected biological properties, for example, targeting to a particular tissue. Such modifications are known in the art and include those that increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), which increase oral availability, increase solubility to allow administration by injection, They modify the metabolism and modify the rate of excretion.
The term halo or halogen refers to any radical of fluorine, chlorine, bromine or iodine.
108
<td>The term</td><td>I rent</td><td>I know</td><td>refers to a</td><td>chain</td><td>from</td>
<td>hydrocarbon that</td><td>can be</td><td>a</td><td>linear chain or</td><td colspan="2">a chain</td>
<td>branched that</td><td>contains the</td><td colspan="2">indicated amount of</td><td>atoms</td><td>from</td>
carbon. For example, C1-C12 alkyl indicates that the group may have 1 to 12 (inclusive) carbon atoms. The term "haloalkyl" refers to an alkyl where one or more hydrogen atoms are replaced by halo and include alkyl moieties where all the hydrogens have been replaced by halo (for example, perfluoroalkyl). The terms "arylalkyl" or "aralkyl" refer to an alkyl moiety where an alkyl hydrogen atom is replaced by an aryl group. Aralkyl includes groups where more than one hydrogen atom has been replaced by an aryl group. Examples of arylalkyl or aralkyl include benzyl, 2-phenylethyl, 3-phenylpropyl, 9-fluorenyl, benzidryl and trifyl groups.
The term "alkylene" refers to a divalent alkyl, for example, -CH2-, -CH2CH2- and -CH2CH2CH2-.
The term "alkenyl" refers to a linear or branched hydrocarbon chain containing 2-12 carbon atoms and having one or more double bonds. Examples of alkenyl groups include, but are not limited to, allyl, propenyl, 2-butenyl, 3-hexenyl and 3-octenyl groups. One of the double bond carbons may optionally be the point of
109 binding of the alkenyl substituent. The term "alkynyl" refers to a linear or branched hydrocarbon chain containing 2-12 carbon atoms and characterized by having one or more triple bonds. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl and 3-hexinyl. One of the triple bond carbons may optionally be the point of attachment of the alkynyl substituent.
The terms "alkylamino and dialkylamino" refer to radicals -NH (alkyl) and -NH (alkyl) 2, respectively. The term "aralkylamino" refers to a radical -NH (aralkyl). The term "alkylaminoalkyl" refers to a (alkyl) NH-alkyl- radical; The term "dialkylaminoalkyl" refers to a 2N-alkyl- (alkyl) radical. The term "alkoxy" refers to a radical -0-alkyl. The term mercapto refers to a radical SH. The term "thioalkoxy" refers to a radical -S-alkyl. The term "thioaryloxy" refers to a radical -S-aryl.
The term "aryl" refers to a monocyclic, bicyclic or tricyclic aromatic hydrocarbon ring system, where any ring atom capable of substitution can be substituted (for example, by one or more substituents). Examples of aryl moieties include, but are not limited to, phenyl, naphthyl and anthracenyl.
110
The term "cycloalkyl," as used herein, includes cyclic, bicyclic, tricyclic or polycyclic non-aromatic hydrocarbon groups having 3 to 12 carbons. Any ring atom that can be substituted can be substituted (for example, by one or more substituents). Cycloalkyl groups may contain fused or spiro rings. Fused rings are rings that share a common carbon atom. Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclohexyl, methylcyclohexyl, adamantyl and norbornyl.
The terms "heterocyclyl" or "heterocyclic group" refer to non-aromatic ring structures of 3 to 14 members (for example, 3 to 14 member rings, more preferably 3 to 7 member rings), whose ring structures include one to four heteroatoms that are independently selected from O, N and S. The heterocyclyl or heterocyclic groups may contain fused or spiro rings. Heterocycles can also be polycycles, where each group has, for example, 5-7 ring members. The term "heterocyclyl" or "heterocyclic group" includes saturated or partially saturated heterocyclyl structures. The term "heteroaryl" refers to an aromatic ring system of 5-14 members (i.e.
111 5-8 member monocyclic, 8-12 member bicyclic or 11-14 member tricyclic) with 1-3 ring heteroatoms if it is monocyclic, 1-6 ring heteroatoms if it is bicyclic or 1-9 ring heteroatoms if it is tricyclic, said ring heteroatoms are independently selected from O, N and S (for example, 1-3, 1-6 or 1-9 ring heteroatoms of N, O or S if it is monocyclic, bicyclic or tricyclic, respectively). Any ring atom that can be substituted can be substituted (for example, by one or more substituents). Heterocyclyl and heteroaryl groups include, for example, thiophene, thiantrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxatiine, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindol, isoindol, indindole indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, fenarsazine, phenothiazine, Furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultanas, sultones and the like. Heterocyclic or heteroaryl ring may be substituted in one or more positions with said substituents, as described herein, such as, for example,
112 halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl , an aromatic or heteroaromatic moiety, -CF3, -CN or the like.
The term "heterocyclylalkyl," as used herein, refers to an alkyl group substituted with a heterocycle group.
The term "cycloalkenyl" refers to non-aromatic monocyclic, bicyclic or tricyclic, partially unsaturated hydrocarbon groups with 5 to 12 carbons, preferably 5 to 8 carbons. The unsaturated carbon may optionally be the point of attachment of the cycloalkenyl substituent. Any ring atom that can be substituted can be substituted (e.g., by one or more substituents). Cycloalkenyl groups may contain fused or spiro rings. Fused rings are rings that share a common carbon atom. Examples of cycloalkenyl moieties include, but are not limited to, cyclohexenyl, cyclohexadienyl or norbornenyl.
The term "heterocycloalkenyl" refers to a 5-10 membered monocyclic ring system, 8-12 membered bicyclic or 11-14 member tricyclic partially
113 non-aromatic saturated with 1-3 heteroatoms if it is monocyclic, 1-6 heteroatoms if it is bicyclic or 1-9 heteroatoms if it is tricyclic, said heteroatoms are independently selected from O, N and S (e.g., 1-3, 1- 6 or 1-9 heteroatoms of the N, O or S ring if it is monocyclic, bicyclic or tricyclic, respectively). The unsaturated carbon or the heteroatom may optionally be the point of attachment of the heterocycloalkenyl substituent. Any ring atom that can be substituted can be substituted (e.g., by one or more substituents). Heterocycloalkenyl groups may contain fused rings. Fused rings are rings that share a common carbon atom. Examples of heterocycloalkenyl include, but are not limited to, tetrahydropyridyl and dihydropyrazyl.
The terms "heteroalkyl" and "heteroaralkyl," as used herein, refer to an alkyl group substituted with a heteroaryl group. Ring heteroatoms of the compounds provided herein include N-0, S (0) and S (O) 2.
The term "oxo" refers to an oxygen atom, which forms a carbonyl when bonded to carbon, an N-oxide when bonded to nitrogen and a sulfoxide or sulfone when bonded to sulfur.
114
The term "acyl" refers to an alkylcarbonyl, cycloalkycarbonyl, arylcarbonyl, heterocyclocarbonyl or heteroarylcarbonyl substituent, any of which may be further substituted (for example, by one or more substituents).
The term substituents refers to a group substituted in an alkyl, cycloalkyl, alkenyl, alkynyl, heterocyclyl, heterocycloalkenyl, cycloalkenyl, aryl or heteroaryl group in any atom that can be substituted from said group. Any atom that can be substituted can be substituted. Unless otherwise specified, such substituents include, non-taxatively, alkyl (eg, straight or branched chain alkyl Cl, C2, C3, C4, C5, C6, C7, C8, C9, CIO, CU, C12), cycloalkyl, haloalkyl (for example, perfluoroalkyl such as CF3), aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, alkenyl, alkynyl, cycloalkenyl, heterocycloalkenyl, alkoxy, haloalkoxy (for example, perfluoroalkoxy) such as OCF, halo, such as OCF carboxy carboxylate, cyano, nitro, amino, alkylamino, SO3H, sulfate, phosphate, methylenedioxy (-O-CH2-Odonde where the oxygens are attached to neighborhood atoms), ethylenedioxy, oxo (not a heteroaryl substituent), thioxo (e.g. C = S) (not a heteroaryl substituent), imino
115 (alkyl, aryl, aralkyl), S (0) nalkyl (where n is 0-2), S (O) n aryl (where n is 0-2), S (O) n heteroaryl (where n is 0-2 ), S (O) n heterocyclyl (where n is 0-2), amine (mono-, di, alkyl, cycloalkyl, aralkyl, heteroaralkyl, aryl, heteroaryl and combinations thereof), ester (alkyl, aralkyl, heteroaralkyl, aryl , heteroaryl), amide (mono, di-, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl and combinations thereof), sulfonamide (mono-, di-, alkyl, aralkyl, heteroaralkyl and combinations thereof). In one aspect, the substituents in a group are independently any individual substituent or any subset of the substituents mentioned above. In another aspect, a substituent may itself be substituted by any of the above substituents.
The term activator, as used herein, refers to an agent that increases (measurably) the activity of wild-type pyruvate kinase R (wtPKR) or causes the increase in the activity of wild-type pyruvate kinase R (wtPKR) to a level greater than reference activity levels of wtPKR or an agent that increases (in a measurable way) the activity of a mutant pyruvate kinase R (mPKR) or causes the increase in the activity of mutant pyruvate kinase R (mPKR) up to
116 level above the reference activity levels of imitating PKR, for example, up to a level that is 20%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the PKR activity wild type e.
The abbreviations Me, Et, Ph, Tf, Nf, Ts, Ms represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, nonafluorobutanesulfonyl, p-toluenesulfonyl and methanesulfonyl, respectively. A more complete list of abbreviations used by organic chemists skilled in the art appears in the first edition of each volume of the Journal of Organic Chemistry; This list is usually presented in a table entitled Standard Abbreviation List. Abbreviations contained in said list and all abbreviations used by organic chemists skilled in the art are incorporated herein by this reference.
Certain activator compounds useful as wild-type and / or mutant PKR activators are those that demonstrate the specificity and activation of the PKR enzyme (wild-type and / or mutant enzyme) in the absence of FBP to a level greater than 10, 15 , 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 99 or 100% in the presence of FBP.
117
TREATMENT METHODS
In one embodiment, a method is provided for treating or preventing a disease, condition or disorder, as described herein (eg, treating) comprising administering a compound, a pharmaceutically acceptable salt of a compound or pharmaceutical composition comprising a compound described herein (for example, a compound of the formula (I), (Ia), (II) or in Table 1).
The compounds and compositions described herein can be administered to cells in culture, for example, in vitro or ex vivo or to a subject, for example, in vivo, to treat, prevent and / or diagnose a variety of disorders, including those described below herein.
As used herein, the term "treat" or "treatment" is defined as the application or administration of a compound, alone or together with a second compound to a subject, for example, a patient, or the application or administration of the compound to a compound. isolated cell or tissue, for example, cell line, of a subject, for example, a patient, who has a disorder (for example, a disorder as described herein), a symptom of a disorder, or a predisposition towards a disorder, with the purpose of curing, healing, relieving, dissipating, modifying,
118 improve or affect the disorder, one or more symptoms of the disorder or predisposition towards the disorder (e.g., to prevent at least one symptom of the disorder or to delay the onset of at least one symptom of the disorder).
As used herein, an amount of an effective compound to treat a disorder or a therapeutically effective amount refers to an amount of the compound that is effective, upon administration of a single or multiple dose to a subject, to treat a cell or to cure, relieve, dissipate or improve a subject who has a disorder beyond what is expected in the absence of such treatment.
Tai as used herein, an amount of a compound, effective to prevent a disorder, or a prophylactically effective amount of the compound refers to an effective amount, after administration of a single dose or multiple doses to the subject, to prevent or delay the onset of the onset or recurrence of a disorder or symptom of the disorder.
As used herein, the term "subject" is intended to include human and non-human animals. Examples of human subjects include a human patient who has a disorder, for example, a disorder described herein or a normal subject. The term nonhuman animals
119 includes all vertebrates, for example, non-mammals (such as chickens, amphibians, reptiles) and mammals, such as non-human primates, domesticated animals and / or useful for agricultural activities, for example, sheep, dog, cat, cow, pig, etc.
COMPOSITIONS AND ROUTES OF ADMINISTRATION
The compositions described herein include the compounds described herein (for example, a compound described herein), as well as additional therapeutic agents if any, in amounts effective to achieve a modulation of the disease or symptoms of the disease, including those described herein.
The term "pharmaceutically acceptable carrier or adjuvant" refers to a carrier or adjuvant that can be administered to a patient, together with a compound provided herein and that does not destroy the pharmacological activity thereof and is not toxic when administered in sufficient doses. to administer a therapeutic amount of the compound.
Pharmaceutically acceptable carriers, adjuvants and vehicles that can be used in the pharmaceutical compositions provided herein include, of
120 non-tax mode, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS), such as d-atocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other administration matrices similar polymeric, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, substances based on Cellulose, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, block polymers polyethylene polyoxypropylene, polyethylene glycol and wool grease. Cyclodextrins, such as α, β and y-cyclodextrin, or chemically modified derivatives, such as hydroxyalkylcyclodextrins, including 2 and 3- hydroxypropyl-β-cyclodextrins, or other solubilized derivatives may also be advantageous when used to improve the administration of compounds of the formulas described herein.
121
The pharmaceutical compositions provided herein may be administered orally, parenterally, by inhalation, topically, rectally, nasally, orally, vaginally or through an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions provided herein may contain any conventional non-toxic conventional pharmaceutically acceptable carrier, adjuvant or carrier. In some cases, the pH of the formulation can be adjusted with pharmaceutically acceptable acids, bases or buffers to improve the stability of the formulated compound or its administration form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to methods known in the art using dispersing or wetting agents (such as, for example, Tween 80) and suitable suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a
122 parenterally acceptable non-toxic diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, fixed sterile oils are conventionally used as a solvent or suspending medium. For this purpose, any tasteless fixed oil, including synthetic mono or diglycerides, can be used. Fatty acids, such as oleic acid and its glyceride derivatives, are useful in the preparation of injectables, such as pharmaceutically acceptable natural oils, such as olive oil or castor oil, especially in its polyoxyethylated versions. These oily solutions or suspensions may also contain a long-chain alcoholic diluent or dispersant or carboxymethylcellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms, such as emulsions and / or suspensions. Other commonly used surfactants, such as Tweens, Spans and / or other similar bioavailability emulsifying or enhancing agents that are commonly used in the manufacture of solid, liquid or other pharmaceutically acceptable dosage forms, can also be used for formulation purposes.
123
The pharmaceutical compositions provided herein may be administered orally in any acceptable oral dosage form that includes, non-taxatively, capsules, tablets, emulsions and suspensions, dispersions and aqueous solutions. In the case of tablets for oral use, commonly used carriers include lactose and corn starch. Generally, lubricating agents, such as magnesium stearate, are also added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and / or emulsions are administered orally, the active substance can be suspended or dissolved in an oil phase and combined with emulsifying and / or suspending agents. If desired, certain sweetening and / or flavoring and / or coloring agents can also be added.
The pharmaceutical compositions provided herein may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound provided herein with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and, therefore, melts in the rectum to release the active components. Such materials include, so
124 Non-tax, cocoa butter, beeswax and polyethylene glycols.
The pharmaceutical compositions provided herein may be administered by nasal spray or inhalation. Such compositions are prepared according to methods well known in the art of pharmaceutical formulation and can be prepared as solutions in saline solution, using benzyl alcohol or other preservatives or absorption promoters suitable to enhance bioavailability, fluorocarbons and / or other solubilizing agents. or dispersion known in the art.
When the compositions provided herein comprise a combination of a compound of the formulas described herein and one or more additional prophylactic or therapeutic agents, both the compound and the additional agent should be present at levels of
<td>dosage</td><td>from</td><td>between</td><td>approximately</td><td> 1</td><td>and 100%,</td><td>Y</td><td>plus</td>
<td colspan="2">preferably</td><td>between</td><td>approximately</td><td> 5</td><td>and 95%</td><td>from</td><td>the</td>
<td>dosage</td><td colspan="3">normally administered</td><td>in</td><td colspan="2">A regime</td><td>from</td>
monotherapy Additional agents may be administered separately as part of a multiple dose regimen of the compounds provided herein. Alternatively, these agents may be part of an individual dosage form, mixed in a single composition.
125 with the compounds provided herein.
The compounds described herein may, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly or subcutaneously; or orally, orally, nasally, transmucosally, topically, in an ophthalmic preparation or by inhalation, with a dose that varies between about 0.5 and about 100 mg / kg body weight, alternatively, doses between 1 mg and 1000 mg / dose, every 4 to 120 hours or according to the requirements of the particular drug. The methods herein contemplate the administration of an effective amount of a compound or a composition of a compound to achieve the desired or established effect. In general, the pharmaceutical compositions provided herein will be administered between about 1 and about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that can be combined with the carrier materials to produce a unit dosage form will vary depending on the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% of the active compound (w / w) · Alternatively, said
126 Preparations contain between about 20% and about 80% of the active compound.
Lower or higher doses than those mentioned above may be necessary. Specific treatment and dosage regimens for any particular patient will depend on a variety of factors, including the activity of the specific compound employed, age, body weight, general state of health, sex, diet, time of administration, excretion rate, combination. of drugs, severity or development of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms and the opinion of the attending physician.
After the improvement of the patient's condition, a maintenance dose of a compound, composition or combination provided herein can be administered, if necessary. Subsequently, the dosage or the frequency of administration or both, can be reduced, depending on the symptoms, to a level at which the improved condition is maintained when the symptoms have been alleviated to the desired level. However, patients may require long-term intermittent treatment after the recurrence of disease symptoms.
127
PATIENT SELECTION AND MONITORING
The compounds described herein can activate the mutant PKRs. Accordingly, a patient and / or subject can be selected for treatment using a compound described herein first by evaluating the patient and / or subject to determine if the subject carries a PKR mutation (for example, one of the mutations, such as described herein), and if it is determined that the subject transports a mutation in PKR, which therefore requires activation of the activity of the mutant PKR, and then optionally administering to the subject a compound described herein. A subject can be evaluated if it carries a mutation in PKR using methods known in the art.
EXAMPLES
Example 1. PKR mutant assay
Process:
• The PKR or mutant PKR enzyme solution was diluted in assay buffer.
• First, 2 pL of test compound was added to the wells and then 180 pL of reaction mixture was added.
• The reaction mixture with the test compound was combined except for ADP and the plates were stored for 60
128 minutes at room temperature.
• 20 pL of ADP was added to start the reaction at room temperature and the progress of the reaction was measured as changes in absorbance at 340 nm wavelength at room temperature.
Preparation of the test compound:
• The stock solution of the test compound was prepared at a concentration of 100% DMSO (10 mM) • 1 to 3 dilutions were prepared for 11 points (ie 50 μΐ of the first concentration was added at 100 μΐ, 100 % DMSO to provide 3.33 mM, 50 μΐ of this was added to 100 μΐ of DMSO to provide 1.11 mM and so on).
• Dilution 1 to 100 in the assay (2 μΐ in 200 μΐ) 15 provided an initial concentration of 100 μΜ, decreasing times by 11 points.
Test buffer: 100 mM KOI, 50 mM Tris 7.5, 5 mM MgC12, 1 mM DTT, 0.03% BSA
Reaction mixture: PKR mutant enzyme: 80-400 20 ng / well; ADP: 0.22-1.65 mM; PEP: 0.1-0.5 mM; NADH: 180 uM; LDH: 0.5 units (Sigma # 59023); DTT: 1 mM; BSA: 0.03%.
It was analyzed whether the representative compounds described herein were a wild-type PKR activator, PKRR532W, PKRR479H and PKRG332S with a lower AC50
129 at 500 nM against each wild type / mutant enzyme.
Example 2. PKR WT single point percentage activation test
A compound described herein was diluted with DMSO and analyzed at a concentration of 1 µΜ. The enzyme was diluted in buffer IX: (100 mM KC1, 50 mM Tris 7.5, 5 mM MgC12, 1 mM DTT, 0.03% BSA). First, 2 µΒ of compound solution was added to the wells, and then 180 µΒ of enzyme solution was added. The assays were combined except for ADP and the plates were stored for 60 minutes at RT. 20 μΒ of ADP was added to begin the test and the test result was evaluated using OD340 to SpectraMax. The test was performed at room temperature.
Final concentration: PKR wt (100 ng / well), Tris pH 7.5 (50 mM), KC1 (100 mM), MgC12 (5 mM), ADP (0.48 mM), PEP (0.15 mM), NADH (180 μΜ), LDH (0.5 units, Sigma 59023), DTT (1 mM) and BSA (0.03%).
Example 3. PKR R510Q single point percentage activation test
A compound described herein was diluted with DMSO and analyzed at a concentration of 1 µΜ. The enzyme was diluted in buffer IX: (100 mM KC1, 50 mM Tris 7.5,
130 mM MgC12, 1 mM DTT, 0.03% BSA). First, 2 gL of compound solution was added to the wells, and then 180 gL of enzyme solution was added. The assays were combined except for ADP and the plates were stored for 60 minutes at RT. 20 gL of ADP was added to begin the test and the test result was evaluated using OD340 to SpectraMax. The test was performed at room temperature.
<td></td><td>Concentration</td><td>final:</td><td>PKR R510Q</td><td>(40 ng / well),</td><td>Tris pH</td>
<td> 7,5</td><td>(50 mM), KC1</td><td>(100 mM)</td><td>, MgC12 (5</td><td>mM), ADP (0.2</td><td>mM), PEP</td>
<td> (0,</td><td>11 mM), NADH (</td><td>180 gM),</td><td>LDH (0.5</td><td>units, Sigma</td><td> 59023),</td>
<td>DTT</td><td>(1 mM) and BSA (</td><td> 0,03 %) .</td><td></td><td></td><td></td>
Example 4. PKR R532W single point percentage activation test
A compound described herein was diluted with DMSO and analyzed at a concentration of 1 gM. The enzyme was diluted in buffer IX: (100 mM KC1, 50 mM Tris 7.5, 5 mM MgC12, 1 mM DTT, 0.03% BSA). First 2 gL of compound solution was added to the wells and then 180 gL of enzyme solution was added. The assays were combined except for ADP and the plates were stored for 60 minutes at RT. 20 gL of ADP was added to begin the test and the test result was evaluated using OD340 to SpectraMax. The test was performed at room temperature.
131
Final concentration: PKR R532W (100 ng / well), Tris pH 7.5 (50 mM), KC1 (100 mM), MgC12 (5 mM), ADP (0.36 mM), PEP (0.1 mM), NADH (180 μΜ), LDH (0.5 units, Sigma 59023), DTT (1 mM) and BSA (0.03%).
Example 5. PKR T384W single point percentage activation test
A compound described herein was diluted with DMSO and analyzed at a concentration of 1 µΜ. The enzyme was diluted in buffer IX: (100 mM KC1, 50 mM Tris 7.5, 5 mM MgC12, 1 mM DTT, 0.03% BSA). First, 2 pL of compound solution was added to the wells, and then 180 pL of enzyme solution was added. The assays were combined except for ADP and the plates were stored for 60 minutes at RT. 20 pL of ADP was added to begin the test and the test result was evaluated using OD340 to SpectraMax. The test was performed at room temperature.
Final concentration: soluble PKR T384W (300 ng / well), Tris pH 7.5 (50 mM), KC1 (100 mM), MgC12 (5 mM), ADP (0.08 mM), PEP (0.23 mM) , NADH (180 μΜ), LDH (0.5 units, Sigma 59023), DTT (1 mM) and BSA (0.03%).
Having thus described various aspects of various modalities, it should be understood that various alterations will easily occur to those skilled in the art,
132 Modifications and improvements. Such alterations , modifications and improvements are intended to be part of this description and are intended to be within the spirit and scope of the invention. Accordingly, the description and drawings above are by way of example only.
133
NEW OF THE INVENTION
Having described the present invention as above, it is considered as a novelty and, therefore, the content in the following is claimed as property:
CLAIMS
Contents13
300 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70 Sheet 71 Sheet 72 Sheet 73 Sheet 74 Sheet 75 Sheet 76 Sheet 77 Sheet 78 Sheet 79 Sheet 80 Sheet 81 Sheet 82 Sheet 83 Sheet 84 Sheet 85 Sheet 86 Sheet 87 Sheet 88 Sheet 89 Sheet 90 Sheet 91 Sheet 92 Sheet 93 Sheet 94 Sheet 95 Sheet 96 Sheet 97 Sheet 98 Sheet 99 Sheet 100 Sheet 101 Sheet 102 Sheet 103 Sheet 104 Sheet 105 Sheet 106 Sheet 107 Sheet 108 Sheet 109 Sheet 110 Sheet 111 Sheet 112 Sheet 113 Sheet 114 Sheet 115 Sheet 116 Sheet 117 Sheet 118 Sheet 119 Sheet 120 Sheet 121 Sheet 122 Sheet 123 Sheet 124 Sheet 125 Sheet 126 Sheet 127 Sheet 128 Sheet 129 Sheet 130 Sheet 131 Sheet 132 Sheet 133 Sheet 134 Sheet 135 Sheet 136 Sheet 137 Sheet 138 Sheet 139 Sheet 140 Sheet 141 Sheet 142 Sheet 143 Sheet 144 Sheet 145 Sheet 146 Sheet 147 Sheet 148 Sheet 149 Sheet 150 Sheet 151 Sheet 152 Sheet 153 Sheet 154 Sheet 155 Sheet 156 Sheet 157 Sheet 158 Sheet 159 Sheet 160 Sheet 161 Sheet 162 Sheet 163 Sheet 164 Sheet 165 Sheet 166 Sheet 167 Sheet 168 Sheet 169 Sheet 170 Sheet 171 Sheet 172 Sheet 173 Sheet 174 Sheet 175 Sheet 176 Sheet 177 Sheet 178 Sheet 179 Sheet 180 Sheet 181 Sheet 182 Sheet 183 Sheet 184 Sheet 185 Sheet 186 Sheet 187 Sheet 188 Sheet 189 Sheet 190 Sheet 191 Sheet 192 Sheet 193 Sheet 194 Sheet 195 Sheet 196 Sheet 197 Sheet 198 Sheet 199 Sheet 200 Sheet 201 Sheet 202 Sheet 203 Sheet 204 Sheet 205 Sheet 206 Sheet 207 Sheet 208 Sheet 209 Sheet 210 Sheet 211 Sheet 212 Sheet 213 Sheet 214 Sheet 215 Sheet 216 Sheet 217 Sheet 218 Sheet 219 Sheet 220 Sheet 221 Sheet 222 Sheet 223 Sheet 224 Sheet 225 Sheet 226 Sheet 227 Sheet 228 Sheet 229 Sheet 230 Sheet 231 Sheet 232 Sheet 233 Sheet 234 Sheet 235 Sheet 236 Sheet 237 Sheet 238 Sheet 239 Sheet 240 Sheet 241 Sheet 242 Sheet 243 Sheet 244 Sheet 245 Sheet 246 Sheet 247 Sheet 248 Sheet 249 Sheet 250 Sheet 251 Sheet 252 Sheet 253 Sheet 254 Sheet 255 Sheet 256 Sheet 257 Sheet 258 Sheet 259 Sheet 260 Sheet 261 Sheet 262 Sheet 263 Sheet 264 Sheet 265 Sheet 266 Sheet 267 Sheet 268 Sheet 269 Sheet 270 Sheet 271 Sheet 272 Sheet 273 Sheet 274 Sheet 275 Sheet 276 Sheet 277 Sheet 278 Sheet 279 Sheet 280 Sheet 281 Sheet 282 Sheet 283 Sheet 284 Sheet 285 Sheet 286 Sheet 287 Sheet 288 Sheet 289 Sheet 290 Sheet 291 Sheet 292 Sheet 293 Sheet 294 Sheet 295 Sheet 296 Sheet 297 Sheet 298 Sheet 299 Sheet 300
94 members in 29 offices
Priority claims7
| Document | Office | Kind | Date |
|---|---|---|---|
| 201161482171 | United States of America | P | |
| 201161482171 | United States of America | P | |
| 61482171 | United States of America | – | |
| 2012036412 | United States of America | W | |
| 2012036412 | United States of America | W | |
| US201161482171P | – | – | – |
| WO2012US36412 | – | – | – |
Members94
| Document | Office | Kind | |
|---|---|---|---|
| CA2834602A1 | Canada | A1 | |
| CA3088328A1 | Canada | A1 | |
| WO2012151451A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2012250688A1 | Australia | A1 | |
| SG194697A1 | Singapore | A1 | |
| IL229178A0 | Israel | A0 | |
| IL229178D0 | Israel | D0 | |
| PH12013502241A1 | Philippines | A1 | |
| KR20140028008A | Republic of Korea | A | |
| EP2704721A1 | European Patent Office (EPO) | A1 | |
| CN103764147A | China | A | |
| JP2014513133A | Japan | A | |
| MX2013012787A | Mexico | A | |
| US2014194402A1 | United States of America | A1 | |
| RU2013153388A | Russian Federation | A | |
| US9193701B2 | United States of America | B2 | |
| US2016106742A1 | United States of America | A1 | |
| ZA201308012B | South Africa | B | |
| SG10201609196QA | Singapore | A | |
| JP2017019839A | Japan | A | |
| AU2012250688B2 | Australia | B2 | |
| US9682080B2 | United States of America | B2 | |
| AU2017221860A1 | Australia | A1 | |
| US2017290825A1 | United States of America | A1 | |
| JP6272754B2 | Japan | B2 | |
| JP6272967B2 | Japan | B2 | |
| PH12017501176A1 | Philippines | A1 | |
| JP2018027985A | Japan | A | |
| EP2704721B1 | European Patent Office (EPO) | B1 | |
| CN103764147B | China | B | |
| US9980961B2 | United States of America | B2 | |
| PT2704721T | Portugal | T | |
| KR101873543B1 | Republic of Korea | B1 | |
| BR112013028422A2 | Brazil | A2 | |
| DK2704721T3 | Denmark | T3 | |
| KR20180079451A | Republic of Korea | A | |
| LT2704721T | Lithuania | T | |
| ES2675903T3 | Spain | T3 | |
| TR2018009699T4 | Türkiye | T4 | |
| TR201809699T4 | Türkiye | T4 | |
| HRP20180863T1 | Croatia | T1 | |
| CN108451955A | China | A | |
| RS57342B1 | Serbia | B1 | |
| SI2704721T1 | Slovenia | T1 | |
| SMT201800354T1 | San Marino | T1 | |
| PL2704721T3 | Poland | T3 | |
| EP3406251A1 | European Patent Office (EPO) | A1 | |
| US2018338970A1 | United States of America | A1 | |
| RU2675656C2 | Russian Federation | C2 | |
| HUE039269T2 | Hungary | T2 | |
| ME03074B | Montenegro | B | |
| RU2017145066A | Russian Federation | A | |
| CY1120374T1 | Cyprus | T1 | |
| MX367387BThis record | Mexico | B | |
| PH12016501710A1 | Philippines | A1 | |
| KR102024027B1 | Republic of Korea | B1 | |
| MX2019009856A | Mexico | A | |
| AU2017221860B2 | Australia | B2 | |
| JP6603293B2 | Japan | B2 | |
| AU2020200700A1 | Australia | A1 | |
| US10632114B2 | United States of America | B2 | |
| IL229178A | Israel | A | |
| IL229178B | Israel | B | |
| US2020289502A1 | United States of America | A1 | |
| IL276414A | Israel | A | |
| IL276414D0 | Israel | D0 | |
| CA2834602C | Canada | C | |
| RU2017145066A3 | Russian Federation | A3 | |
| US2021220351A1 | United States of America | A1 | |
| BR112013028422B1 | Brazil | B1 | |
| BR112013028422B8 | Brazil | B8 | |
| CN108451955B | China | B | |
| AU2020200700B2 | Australia | B2 | |
| CN114432312A | China | A | |
| PH12017501176B1 | Philippines | B1 | |
| IL276414B2 | Israel | B2 | |
| US11793806B2 | United States of America | B2 | |
| EP3406251B1 | European Patent Office (EPO) | B1 | |
| PT3406251T | Portugal | T | |
| LT3406251T | Lithuania | T | |
| FI3406251T3 | Finland | T3 | |
| DK3406251T3 | Denmark | T3 | |
| SMT202400081T1 | San Marino | T1 | |
| RS65215B1 | Serbia | B1 | |
| HRP20240225T1 | Croatia | T1 | |
| PL3406251T3 | Poland | T3 | |
| ES2970938T3 | Spain | T3 | |
| SI3406251T1 | Slovenia | T1 | |
| HUE065700T2 | Hungary | T2 | |
| CN114432312B | China | B | |
| US2024277701A1 | United States of America | A1 | |
| MX386224B | Mexico | B | |
| US12377093B2 | United States of America | B2 | |
| US2025332161A1 | United States of America | A1 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Grant or registrationFG | FG |
Numbers
- Publication
- 367387
- Publication, DOCDB
- 367387
- Publication, EPODOC
- MX367387
- Application
- 20130012787
- Application, DOCDB
- 2013012787
- Application, EPODOC
- MX20130012787
Titles2
- Spanish
- ACTIVADORES DE CINASA DE PIRUVATO PARA SU USO EN TERAPIA.
- English
- PIRUVATO CINASE ACTIVATORS FOR USE IN THERAPY.
Classification
- CPC, 25
- A61K31/496
- A61K31/495
- A61K31/4965
- A61K31/497
- A61P7/06
- A61K31/535
- C07D205/04
- C07D213/81
- C07D215/14
- C07D235/06
- C07D241/20
- C07D271/12
- C07D295/192
- C07D333/24
- C07D401/12
- C07D405/12
- C07D417/12
- A61K31/415
- A61K31/4406
- A61K31/47
- C07D241/04
- C07D307/14
- A61P7/00
- C07C13/04
- C07C307/10
- IPC, 3
- A61K31 4965
- A61K31 497
- A61P7 06
